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Abstract We compare and contrast the transit compartment ordinary differ-
ential equation modelling approach with distributed and discrete delay differ-
ential equation models. We focus on Quartino’s extension to the Friberg transit
compartment model of myelosuppression, widely relied upon in the pharma-
ceutical sciences to predict the neutrophil response after chemotherapy, and
on a QSP delay differential equation model of granulopoiesis. We extend the
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Quartino model by considering a general number of transit compartments and
introduce an extra parameter which allows us to decouple the maturation time
from the production rate of cells, and review the well established linear chain
technique from the delay differential equation (DDE) literature which can be
used to reformulate transit compartment models with constant transit rates
as distributed delay DDEs. We perform a state-dependent time rescaling of
the Quartino model in order to apply the linear chain technique and rewrite
the Quartino model as a distributed delay DDE, which yields a discrete de-
lay DDE model in a certain parameter limit. We then perform stability and
bifurcation analyses on the models to situate such studies in a mathematical
pharmacology context.
We show that both the original Friberg and the Quartino extension model
incorrectly define the mean maturation time, essentially treating the prolif-
erative pool as an additional maturation compartment, which can have far
reaching consequences on the development of future models of myelosuppres-
sion in PK/PD.
Keywords Granulopoiesis · mathematical pharmacology · delay differential
equations · bifurcation analyses · transit compartment models · linear chain
technique
1 Introduction
In the pharmaceutical sciences, the concept of lag time, or the delay between
the administration and the absorption of a drug, is a well-established phe-
nomenon which is often accounted for [47]. Physiologically-based pharmacoki-
netic models incorporating absorption models like the ACAT or ADAM [2,29]
were indeed conceived and developed in part to account for the enterohepatic
circulation that contributes to the delay in drug concentrations in the blood
after oral administration. However, regardless of the administration of a xeno-
biotic, various forms of delays are present throughout physiological systems. In
addition to pharmacokinetic lags, systems-level delays play an important role
in determining the pharmacodynamic response to treatment. As examples, in-
tracellular and intrinsic viral delays contribute to more complicated viral load
decay in patients with human immunodeficiency virus being treated with an-
tiretroviral drugs [18], and the hematopoietic system displays multiple delays
along the pathways from the pluripotent hematopoietic stem cells (HSCs) to
terminally differentiated circulating cells [35].
Granulopoiesis, the process of neutrophil production, in particular, exhibits
multiple delays and has been studied in depth owing to the role neutrophils
play in the innate (and adaptive) immune response [37]. Within the phar-
maceutical context, neutropenia is a toxic side effect of chemotherapy, and
impacts heavily on treatment success and overall survival outcomes [48,26].
There is therefore an established interest in mathematical models that can
predict the response to chemotherapeutic drugs [21,19,45] and accurately rep-
resent the feedback mechanisms regulating neutrophil homeostasis [15,30].
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To maintain basal circulating neutrophil concentrations, multipotent pro-
genitor HSCs in the bone marrow differentiate into the myeloid lineage on
their way to becoming circulating neutrophils. After commitment, cells prolif-
erate and undergo several divisions during a phase where cell numbers increase
exponentially. After proliferation, neutrophil progenitors no longer divide. In-
stead, they grow in size and number of receptors before being sequestered into
a marrow reservoir [44], where they either die through apoptosis or transit
into circulation [9]. Once they exit from the bone marrow, neutrophils circu-
late very transiently, with a half-removal time on the order of 7-10 hours [52],
as they either rapidly die or marginate into tissues [44]. Granulopoiesis is con-
trolled by various cytokines, of which granulocyte colony-stimulating factor
(G-CSF) is the principal actor [53]. By binding to receptors on the neutrophil
membranes, G-CSF regulates the rate at which neutrophils are released into
circulation, and modulates up-stream factors (differentiation into the myeloid
lineage, proliferation of upstream neutrophil progenitors, speed of maturation)
to replenish and regulate the concentration of neutrophils in the bone marrow
reservoir. G-CSF is then internalised by the neutrophils and removed from
circulation. In the case of elevated circulating concentrations, G-CSF is also
cleared via a linear, renal pathway [32] and these dual routes of elimination are
important determinants of the PKs of G-CSF [15]. An overview of the process
of neutrophil production is given in Figure 1.
Mathematical representations of granulopoiesis (and other similar physio-
logical delay systems) fall into three classes: transit compartment models where
delays are represented via a chain of first-order ordinary differential equations
(ODEs), distributed delay systems where integro-differential equations repre-
sent a delay that takes a range of values determined through some probability
distribution [8,27,1,49], or delay differential equation (DDE) systems where
the present state depends on past states via fixed or state-dependent delays
[19,6,15] (for more detailed discussions on the various models used in mod-
elling hematopoiesis and chemotherapy-induced neutropenia, see [41] and [13],
respectively).
Here we focus on two models of granulopoiesis in particular: the Quar-
tino model [43] and the Quantitative systems pharmacology (QSP) model of
Craig [15]. The Quartino transit compartment ODE model accounts for the
effects and PKs of endogenous G-CSF and is an extension of the widely-used
Friberg model [21,22], while the QSP granulopoiesis model of [15] is a state-
dependant delay DDE model that incorporates the concentrations of unbound
G-CSF and G-CSF bound to its neutrophil receptors. We will show that the
Quartino model [43] can be reformulated as a distributed delay DDE, which
becomes a discrete-delay DDE in a certain parameter limit. This reformulation
of the Quartino model leads to some additional insight on parameter choices
and will lead us to generalise this model.
Since the maintenance of homeostasis or the pathogenic shift towards
disease-states depend on the longterm behaviour of a given system’s steady
states, stability is an integral concept in physiology. In what follows, we will
study the stability of these three major granulopoiesis model-types (transit
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Fig. 1: An overview of granulopoiesis. As with all blood cells, neutrophils be-
gin as hematopoietic stem cells (HSCs–orange circle) in the bone marrow (pale
yelow background), where they develop. HSCs are capable of self-renewal and
are subject to cell death (dashed arrows). HSCs may also differentiate into
one of the blood cell lines, including the neutrophils (purple circles). After
commitment to the neutrophil lineage, cells undergo a period of proliferative
expansion after which they no longer divide. Post-mitotic neutrophils then
mature, growing in size and gaining receptors. At the end of the maturation
process, cells are then stored in the bone marrow reservoir from which they
egress to reach circulation (pale red background) before removal (by margina-
tion or death). G-CSF acts to modulate the rate of exit from the marrow
reservoir, increase the rates of maturation and proliferation, and to modulate
the rate of differentiation into the neutrophil lineage (G-CSF actions repre-
sented by blue vertical arrows). Figure reproduced from “Towards quantitative
systems pharmacology models of chemotherapy-induced neutropenia”, CPT:
Pharmacometrics and Systems Pharmacology, 2017 (to appear), Craig, M.,
[13] with the permission of Wiley.
compartment, distributed and discrete delay, and QSP) by demonstrating the
relationships and equivalencies between all three formalisms and analysing the
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resulting distributed delay model to provide a better understanding of the role
model selection plays within a treatment context. Accordingly, we will discuss
how these stability results can impact the incorporation and delineation of the
effects of interindividual variability. We will also provide a historical context
for the origins of transit compartment models from distributed delay models
and DDEs.
This paper is divided as follows. We begin in Section 2.1 with an ex-
tension to the common ODE transit compartment model before introduc-
ing the more general distributed and discrete delay models in Section 2.2.
Therein, we discuss the linear chain technique (Section 2.2.1) used to re-
cover a transit compartment model from distributed delay systems. We then
briefly introduce our previously published QSP model including endogenous
G-CSF negative feedback in Section 2.3. The stability of the transit com-
partment/distributed/discrete delay models and the QSP model is analysed
in Section 3 before we undertake bifurcation analyses (Section 4), which we
discuss within the pharmaceutical sciences context in Section 5. We conclude
by discussing our results in Section 6. Many of the proofs are provided in the
appendices at the end.
2 Modelling granulopoiesis: three different approaches to handling
delays
2.1 Transit compartment model with endogenous G-CSF
The Friberg model [21] is perhaps the most well-known model of myelosup-
pression after chemotherapy in the pharmaceutical sciences [13]. Five com-
partments are used to represent the HSCs and early progenitors, circulating
neutrophils, and the transit between the proliferative and circulative states.
A feedback mechanism on the rate of proliferation determines the extent of
myelosuppression of the chemotherapeutic agent. The model has been shown
to generically represent a variety of chemotherapeutic drugs [22] and has been
widely adopted in PK/PD studies of anti-cancer drugs. We write a generalised
version of this model as
dP
dt
=
(
kP(1− EDrug)
(
N0
N(t)
)γ
− ktr
)
P
dT1
dt
= ktrP − aT1 (2.1)
dTj
dt
= a(Tj−1 − Tj), j = 2, . . . , n
dN
dt
= aTn − kcircN,
which reduces to the Friberg model if we set kP = ktr = a and n = 3. Here,
P is the concentration of proliferating progenitors, Tj is the j
th post-mitotic
transit compartment, and N is the circulating neutrophil concentration (all in
6 Daniel Caˆmara De Souza, Morgan Craig et al.
(OFV 31 units lower) compared to the corresponding model
with empirical functions on the proliferation rate and matu-
ration time. A comparison between the two feedback func-
tions shows that the amplitude is larger for the G-CSF
feedback than the empirical function (Fig. 3). It was also
observed that the feedback amplitude is larger following
FEC treat ent (course 1–3) than docetaxel treatment (course
3–6). The amplified feedback due to increase in G-CSF
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Fig. 1 Observed individual profiles of endogenous G-CSF (blue) and neutrophils (red) following FEC (left) and docetaxel (right) treatment. The model prediction
of a typical patient following corresponding treatments is shown in solid lines.
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Fig. 2 The integrated G-CSF-myelosuppression model describing the dynamics of endogenous G-CSF and neutrophils following chemotherapy. For the
myelosuppression model the parameters are baseline neutrophil count (ANC0), mean maturation time (MMT=5/ktr), the half-life of neutrophils in circulation
(t½circ=LN(2)/kcirc), the feedback parameters of G-CSF on neutrophil proliferation (γ) and transit time (β) and the drug related effect (Edrug). The estimated
parameters for the G-CSF turnover model are baseline G-CSF (GCSF0), nonspecific elimination rate constant (ke) and ANC-dependent elimination rate constant
(kANC) and cortisol-induced G-CSF release (DOSEcort) and the half-life of cortisol-induced G-CSF release (t1/2 cort=LN(2)/kcort).
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Fig. 2: The integr ted G-C F-myelosuppressio model describing the dynam-
ics of endogenous G-CSF and neutrophils following chemotherapy. For the
myelosuppression model the parameters are baseline neutrophil count (ANC0),
mean maturation time (MMT=5/ktr), the half-life of neutrophils in circula-
tion (t1/2circ=ln(2)/kcirc), the feedback parameters of G-CSF on neutrophil
proliferation (γ) and transit time (β) and the drug related effect (Edrug).
The estimated parameters for the G-CSF turnover model are baseline G-CSF
(GCSF0), nonspecific elimination rate constant (ke) and ANC-dependent elim-
ination rate constant (kANC) and cortisol-induced G-CSF release (DOSEcort)
and the half-life of cortisol-induced G-CSF release (t1/2cort=ln(2)/kcort). Fig-
ure reproduced from “Characterization of endogenous G-CSF and the inverse
correlation to chemotherapy-induced neutropenia in patients with breast can-
cer using population modeling”, Pharmaceutical Research, 31, 2014, pp. 3396,
Quartino, A.L. et al., [43] with the permission of Springer.
units of 109 cells/L), while kP is the rate of proliferation in the progenitor cell
pool, ktr and a are the transit rates between the maturation compartments,
and kcirc is the rate of neutrophil exit from circulation (all in units of h
−1).
An extension to the Friberg model, which we will refer to as the Quar-
tino model, is presented in [43] and models the myelosuppressive effects of
chemotherapy on progenitor and circulating neutrophils, the endogenous G-
CSF response, and the effect of the administration of a glucocorticoid to induce
a rapid increase in G-CSF. A model schematic is given in Figure 2. For our
purposes, we can discount the administration of the glucocorticoid prior to
chemotherapy and ignore the corresponding model terms. We write a gener-
Transit and lifespan in neutrophil production: implications for drug intervention 7
alised version of the model as
dP
dt
= P
(
kP(1− EDrug)
(
G
G0
)γ
− ktr
(
G
G0
)β)
(2.2a)
dT1
dt
=
(
G
G0
)β
(ktrP − aT1) (2.2b)
dTj
dt
= a
(
G
G0
)β
(Tj−1 − Tj), j = 2, . . . , n (2.2c)
dN
dt
= a
(
G
G0
)β
Tn − kcircN (2.2d)
dG
dt
= kin − (ke + kANCN)G, (2.2e)
where G is the circulating G-CSF concentration (ng/L), kANC is the neutrophil-
dependent rate of G-CSF elimination (h−1), ke is the G-CSF nonspecific elim-
ination rate (h−1), (G/G0)γ is the feedback on the proliferation rate from
circulating G-CSF concentrations, and (G/G0)
β reflects the G-CSF feedback
on the maturation rate. In most of the current work we do not consider the
chemotherapeutic agent and set EDrug = 0, unless otherwise stated.
We let P0, N0 and G0 denote the homeostasis values of P , N and G re-
spectively, obtained by setting
dP
dt
=
dTj
dt
=
dN
dt
=
dG
dt
= 0 (2.3)
in (2.2). In both the Friberg and Quartino models, it is a modelling assumption
that
kP = ktr. (2.4)
The condition (2.4) is required in the Friberg model (2.1) to ensure that N =
N0 at homeostasis, and in the Quartino model (2.2) to ensure that G = G0
at homeostasis. If G0 were not the homeostasis value of G, it would be hard
to justify the (G/G0)
β terms appearing throughout the model, and the model
ought to take a different form. Consequently we enforce the condition (2.4)
throughout, and always assume that ktr = kP as in [43].
To see why we generalise the model by including a new parameter a, note
that at homeostasis the rate of production of proliferating cells, the rate that
cells leave proliferation to enter the first transit compartment, the rate they
leave the last transit compartment to enter circulation and the rate that they
leave circulation must all be equal. In both models this results in
kPP0 = ktrP0 = kcircN0. (2.5)
The production rate in (2.5) is completely independent of the maturation
time of the cells; provided cells both enter and leave maturation at the rate
given by (2.5), changing the maturation time τ would only change the total
number of cells that are in maturation (which is τkPP0), but will not change the
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Parameter Units Typical estimate (% RSE)
N0 109 cells/L 3.53 (5)
ktr = kP h−1 0.03759
γ - 0.444 (4)
β - 0.234 (8)
G0 ng/L 24.3 (8)
ke h−1 0.592 (32)
kANC h/109 cells/L 5.64
kcirc h
−1 0.099
kin h
−1 498.1792
Table 1: Parameter values from [43] for the parameters of interest in this
study. The mean value of the distributed delay in (2.31) is given by τ = n/a,
or τ = 106.41 hours.
production rate in (2.5). We will see below that at homeostasis the maturation
time τ for both models is given by
τ =
n
a
. (2.6)
Fixing a = ktr leads to two related modelling problems. First if we regard
a = ktr as known then, since n is an integer, equation (2.6) only allows for
certain discrete values of the delay τ . On the other hand, if as is more usual we
suppose that τ is known then choosing n an integer and imposing that a = ktr
in (2.6) uniquely determines the value of ktr in (2.6), which in turn determines
the production rate in (2.5). But we already noted that the production rate
at homeostasis kPP0 and the maturation time τ are independent.
In Quartino [43] a mean maturation time is defined by MMT = (n+1)/ktr.
Presumably the authors counted n transit compartments plus one proliferation
compartment. By showing the equivalence of the generalised Quartino model
(2.2) to a distributed delay DDE in Section 2.2 we will find both the mean and
variance of the delay, and show that even if a = ktr the correct formula for
the mean maturation time should be MMT = n/ktr, corresponding to (2.6),
and not the formula used in Quartino [43].
In the following sections we will consider general values of the parameters
a and n, but will take the values of the remaining parameters from [43]; these
values are tabulated in Table 1. To satisfy the homeostasis conditions (2.3) we
obtain
Tj =
N0kcirc
a
, j = 1, . . . , n, P0 =
N0kcirc
ktr
, (2.7)
and the parameter constraint
kin = G0(ke + kANCN0). (2.8)
At homeostasis the total number of cells in the n maturation compartments
is N0kcircn/a. Dividing this by the production rate given by (2.5) gives the
average maturation time τ = n/a as stated in (2.6).
Notice that if a = ktr as in [43] then at steady state we have Tj = P for
all the transit compartments. In [43] the model (2.2) is considered with initial
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conditions at time t = 0 equal to the steady-state values (which is natural for a
chemotherapy study before the chemotherapeutic agent is administered), but
we will consider the behaviour of the model for general non-negative initial
conditions. Proof of the positivity of solutions to the Quartino system (2.2)
can be found in Appendix B.1.
2.2 Gamma-distributed delay representation of the transit compartment
granulopoiesis models
Distributed delay DDEs come in many varieties, but a reasonably general form
is
dN
dt
= f
(
t,N(t),
∫ t
−∞
P (s)gpa(t− s)ds
)
(2.9)
= f
(
t,N(t),
∫ ∞
0
P (t− u)gpa(u)du
)
.
In simpler examples P (t) ≡ N(t), but P (t) can also be a separate variable
defined by its own differential equation (as is the case in the granulopoiesis
models considered in this work). The function gpa(u) is a probability density
with ∫ ∞
0
gpa(u)du = 1. (2.10)
So, rather than the dynamics of N(t) being determined by the current value
of P (t), the integral distributes the effect of P across its previous values. In
this work we will restrict attention to the gamma distribution, though other
distributions do arise, in particular the uniform distribution. We write the
probability density function gpa of the gamma distribution as
gpa(t) =
aptp−1e−at
Γ (p)
, (2.11)
where Γ (p) is the gamma function. When n is a positive integer Γ (n) = (n−1)!,
and the gamma function generalises the factorial function to real numbers p
with Γ (p) = (p − 1)Γ (p − 1) for any p > 0. The real positive parameters a
and p determine the shape and rate of the distribution with the mean delay τ
given by
τ = p/a, (2.12)
and standard deviation σ2 = p/a2. If p and a are taken to infinity with their
ratio τ held constant then the variance decreases to zero and the probability
density function gpa(t) becomes narrower and taller and approaches the δ-
function δ(t − τ). In this limit the distributed delay DDE (2.9) reduces to a
discrete delay DDE
dN
dt
= f(t,N(t), P (t− τ)). (2.13)
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So discrete delay DDEs can be thought of as a limiting case of distributed
delay DDEs. We will see below that when p = n an integer, we can rewrite a
gamma distributed DDE as an ODE, so gamma distributed DDEs provide a
link between ODEs and discrete delay DDE models.
2.2.1 The Linear Chain Technique
The linear chain technique is used to convert some distributed delay differ-
ential equations (DDEs) into a corresponding system of ordinary differential
equations (ODEs), or vice versa. The technique dates back at least to the
work of Vogel in the 1960s [50,51], and first appears in the English literature
in the work of MacDonald [33,34] who called the method the linear chain trick.
Most authors continue to use that name, but we prefer linear chain technique,
because, as we will see, there is a true equivalency between the differential
equation systems, and no trick is involved. It is usually more convenient to
formulate problems as ODEs for numerical simulation, but sometimes more
convenient to formulate them as DDEs for analysis. The linear chain technique
is well-known and used in population biology and mathematical epidemiology,
but is as yet not as well-known in other fields. The method has been inde-
pendently rediscovered several times over the decades, being referred to as the
fixed boxcartrain method by Goudriaan [24], and recently used by Krzyzan-
ski [31] in a pharmaceutical sciences setting. There are several variants on this
technique, and descriptions can be found in many places including [28,34,46],
but the simplest application is for a gamma distributed delay, for which we
will detail the steps here.
The probability density function (2.11) has the property that for p 6= 1
d
dt
gpa(t) =
(p− 1)aptp−2e−at
Γ (p)
− a
p+1tp−1e−at
Γ (p)
= a
(
ap−1tp−2e−at
Γ (p− 1) −
aptp−1e−at
Γ (p)
)
= a(gp−1a (t)− gpa(t)). (2.14)
While for p = 1
d
dt
g1a(t) =
d
dt
(ae−at) = −ag1a(t). (2.15)
Models of the form (2.9),(2.11) can in principle be considered for any real
positive value of p, but in practice nearly all authors only consider p = n
a positive integer (one exception is [8]), because then equations (2.14),(2.15)
allow the distributed DDE to be reduced to an ODE. To do this let
Tj(t) =
∫ t
−∞
P (s)gja(t− s) ds =
∫ ∞
0
P (t− u)gja(u) du, j = 1, . . . , n. (2.16)
Then equation (2.9) can be rewritten as an ODE
dN
dt
= f (t,N(t), Tn(t)) . (2.17)
Transit and lifespan in neutrophil production: implications for drug intervention 11
Differentiating (2.16), using Leibniz rule for j > 1 (noting that gja(0) = 0 for
j > 1) we obtain
dTj
dt
= P (t)gja(0) +
∫ t
−∞
P (s)
d
dt
gja(t− s) ds
=
∫ t
−∞
P (s)a(gj−1a (t− s)− gja(t− s)) ds
= a(Tj−1(t)− Tj(t)), j = {2, 3, . . . , n}. (2.18)
While for j = 1 (noting that g1a(0) = a)
dT1
dt
= P (t)g1a(0) +
∫ t
−∞
P (s)
d
dt
g1a(t− s) ds = a(P (t)− T1(t)). (2.19)
Together equations (2.17),(2.18),(2.19) redefine the (nonlinear) distributed de-
lay DDE (2.9) as a system of n+1 ODEs. General DDEs can be posed as infinite
dimensional dynamical systems, which introduces considerable mathematical
difficulties, so being able to reduce some DDE models to finite-dimensional
ODEs is mathematically very advantageous.
To complete the relationship between the distributed delay DDE (2.9) and
the system of ODEs (2.17),(2.18),(2.19) we should take some care with the
initial conditions. The distributed DDE (2.9) has infinite memory, and so to
solve as an initial value problem from time t = 0 we need to define a history
function P (t) for all t 6 0, so that the right hand-side of (2.9) can be evaluated.
With P (t) so defined, for the DDE and ODE reduction to have equivalent
solutions, by (2.16) the ODE must have initial conditions
Tj(0) =
∫ 0
−∞
P (s)gja(−s) ds =
∫ ∞
0
P (s)gja(s) ds j = 1, . . . , n. (2.20)
If it is assumed that P (t) = P0, a constant for all t 6 0 then, using (2.10), we
see that (2.20) reduces to
Tj(0) = P0
∫ ∞
0
gja(s) ds = P0, j = 1, . . . , n. (2.21)
It is natural to ask if we can also go the other way; does a solution of the
system of ODEs (2.17),(2.18),(2.19), define a solution of the distributed DDE
(2.9)? It follows immediately from (2.21) that a solution of the ODE system
with initial conditions P (0) = Tj(0) for j = 1, . . . , n does define a solution
of (2.9). The equivalence for more general initial conditions for the ODE has
also been established; in that case the ODE initial conditions define a finite
number of constraints on the history function P (t) for t 6 0, which do not
uniquely define P (t), and the ODE defines a solution of the distributed DDE
(2.9) for all choices of P (t) that satisfy the constraints [11,34].
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2.2.2 Gamma-distributed and discrete delay representations of transit
compartment granulopoiesis models
The linear chain technique of Section 2.2.1 can be applied to establish the
equivalence between transit compartment ODE models and corresponding dis-
tributed delay DDEs. Consider first the distributed DDE system
dP
dt
=
(
kP(1− EDrug)
(
N0
N(t)
)γ
− ktr
)
P
dN
dt
= −kcircN + ktr
∫ t
−∞
P (s)gna (t− s)ds.
(2.22)
We define Tj(t) by
Tj(t) =
∫ t
−∞
ktr
a
P (s)gja(t− s) ds, j = 1, . . . , n, (2.23)
which corresponds to (2.16) with ktrP (s)/a replacing P (s). Writing the equa-
tion for N(t) as
dN
dt
= −kcircN + a
∫ t
−∞
ktr
a
P (s)gna (t− s)ds, (2.24)
and applying the linear chain technique of Section 2.2.1 we obtain the gener-
alised Friberg transition compartment model of myelosuppression (2.1). Taking
a = ktr and n = 3 gives the Friberg model as stated in [21], as has already
been noted in [4].
While it is necessary to set a = ktr in (2.22) to recover the model as stated
in [21], equation (2.1) defines a transit compartment model for other values
of a also, and both the system of ODEs (2.1) and the distributed DDE (2.22)
can be considered for general values a > 0.
The extended Quartino endogenous G-CSF model [43] as stated in (2.2)
and discussed in Section 2.1 cannot be stated simply as a distributed delay
DDE via the linear chain technique. The maturation time in the Quartino
model instead of being constant is state-dependent with the rate constants for
the passage through each transit compartment given by
a
(
G(t)
G0
)β
,
which varies as G(t) varies; it reduces to the same value as for the Friberg
model only if G(t) = G0. In contrast, the derivation of (2.14), which is essen-
tial in the linear chain technique, requires that the rate constant a (and the
power p) be constant, so to apply the linear chain technique the profile of the
probability density function must remain constant and cannot vary with time
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or the solution. Thus, while it might be tempting to consider a distributed
DDE of the form
dP
dt
= P
(
kP
(
G
G0
)γ
− ktr
(
G
G0
)β)
dN
dt
= −kcircN + ktr
(
G
G0
)β ∫ t
−∞
P (s)gna (t− s) ds
dG
dt
= kin − (ke + kANCN)G,
(2.25)
if we set a = ktr(G(t))/G0)
β , then it is not possible to reduce this model
to a system of ODEs because the derivation of (2.14) fails when a is time-
dependent. Instead we could consider the model
dP
dt
= P
(
kP
(
G
G0
)γ
− ktr
(
G
G0
)β)
dN
dt
= −kcircN + ktr
∫ t
−∞
(
G(s)
G0
)β
P (s)gna (t− s) ds
dG
dt
= kin − (ke + kANCN)G,
(2.26)
and apply the linear chain technique with
Tj(t) =
∫ t
−∞
ktr
a
(
G(s)
G0
)β
P (s)gja(t− s) ds, j = 1, . . . , n. (2.27)
to obtain the transit compartment model
dP
dt
= P
(
kP
(
G
G0
)γ
− ktr
(
G
G0
)β)
dT1
dt
= ktr
(
G
G0
)β
P (t)− aT1(t)
dTj
dt
= a(Tj−1(t)− Tj(t)), j = {2, 3, . . . , n}
dN
dt
= aTn(t)− kcircN
dG
dt
= kin − (ke + kANCN)G,
(2.28)
which is similar to the Quartino model (2.2), but missing the (G(t)/G0)
β
factors in all the Tj transit terms, and consequently does not model the effect
of G-CSF on the maturation rate.
To write the Quartino model (2.2) as a distributed DDE, we first remove
the state-dependency of the delays by rescaling time. Define a new time tˆ(t)
by
dtˆ
dt
=
(
G(t)
G0
)β
, tˆ(0) = 0. (2.29)
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By Theorem 2 the right-hand side of (2.29) is strictly positive for t > 0
so dtˆdt > 0 and the new time variable tˆ(t) is a strictly monotonic increasing
function of t. Then we see that
dTj
dtˆ
=
dt
dtˆ
dTj
dt
=
(
G0
G(tˆ)
)β
a
(
G(tˆ)
G0
)β
(Tj−1 − Tj) = a(Tj−1 − Tj).
Strictly speaking we should define new variables G˜(tˆ) = G(t), but following
common practice we suppress the tildes and reuse the same variable names.
Applying the same time-rescaling to all the equations we rewrite the Quartino
model (2.2) as
dP
dtˆ
=
(
kP
(
G(tˆ)
G0
)γ−β
− ktr
)
P (tˆ)
dT1
dtˆ
= ktrP (tˆ)− aT1(tˆ)
dTj
dtˆ
= a(Tj−1(tˆ)− Tj(tˆ)), j = 2, . . . , n
dN
dtˆ
= aTn(tˆ)−
(
G0
G(tˆ)
)β
kcircN(tˆ)
dG
dtˆ
=
(
G0
G(tˆ)
)β (
kin − (ke + kANCN(tˆ))G(tˆ)
)
.
(2.30)
We refer to (2.30) as the time-rescaled Quartino model. Since the time rescaling
satisfies tˆ(0) = 0, the initial conditions for the Quartino model (2.2) at t = 0
and the time-rescaled Quartino model (2.30) at time tˆ = 0 are the same, and
these two equations given equivalent solutions.
The time-rescaled Quartino model (2.30) has constant transition rates be-
tween the transit compartments, and consequently we can apply the linear
chain technique to derive (2.30) from
dP
dtˆ
=
(
kP
(
G(tˆ)
G0
)γ−β
− ktr
)
P (tˆ)
dN
dtˆ
= −
(
G0
G(tˆ)
)β
kcircN(tˆ) + ktr
∫ tˆ
−∞
P (s)gna (tˆ− s) ds
dG
dtˆ
=
(
G0
G(tˆ)
)β (
kin − (ke + kANCN(tˆ))G(tˆ)
)
,
(2.31)
by letting
Tj(tˆ) =
∫ tˆ
−∞
ktr
a
P (s)gja(tˆ− s) ds, j = 1, . . . , n. (2.32)
To define an initial value problem for the distributed delay DDE (2.31) we
need to specify N(0), G(0) and P (tˆ) for tˆ 6 0. This in turn defines initial
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conditions for both the time-rescaled Quartino model (2.30) and the Quartino
model (2.2) with Tj(0) given by evaluating (2.32) with tˆ = 0. If P (tˆ) is constant
for tˆ 6 0 then (2.32) implies that Tj(0) = ktrP (0)/a, so there is an immediate
equivalence between all three models for such initial conditions. Even if the
Quartino model (2.2) were considered with different initial conditions, there
is still a direct equivalence to the time-rescaled Quartino model (2.30), and as
noted at the end of Section 2.2.1, also to the distributed DDE model (2.31).
Consequently we have three equivalent forms of the same model, with a direct
correspondence between the solutions of the differential equation systems (2.2)
and (2.30) and (2.31).
Recalling (2.12) the mean value of the distributed delay in (2.31) is τ =
n/a. The time rescaling (2.29) is trivial at homeostasis when G(t) = G0, so
this also implies that the mean maturation delay is τ = n/a in the Quartino
model (2.2) (and fact that we already derived by a different argument in (2.6)).
Fixing a = ktr only allows a very granular control of the mean delay in the
ODE model by varying the integer n. Mathematically it is more convenient to
fix the delay τ > 0 and use n and a to control the shape of the distribution.
For the distributed DDE model (2.31) we do not even need n to be an integer.
Recalling (2.10), in the limit as n → ∞ and a → ∞ with τ = n/a fixed, the
distributed delay DDE (2.31) reduces to the discrete delay DDE
dP
dtˆ
=
(
kP
(
G(tˆ)
G0
)γ−β
− ktr
)
P (tˆ)
dN
dtˆ
= −
(
G0
G(tˆ)
)β
kcircN(tˆ) + ktrP (tˆ− τ)
dG
dtˆ
=
(
G0
G(tˆ)
)β (
kin − (ke + kANCN(tˆ))G(tˆ)
)
.
(2.33)
We remark that in the discrete delay DDE (2.33) the delay τ is constant in the
rescaled time-variable tˆ, just as the (same) mean delay τ = n/a is constant in
the distributed delay DDE (2.31). In contrast the mean maturation time α(t)
in the Quartino model (2.2) varies with G(t) and satisfies
tˆ(t− α(t)) = tˆ(t)− τ,
where tˆ(t) satisfies (2.29). If G is held constant (but not necessarily equal to
G0), this gives a mean maturation time α in the Quartino model (2.2) of
α =
n
a(G/G0)β
=
τ
(G/G0)β
.
For the case of time-varying G(t), the evolution of the mean maturation delay
α(t) is defined by a differential equation (A.2), which we derive in Appendix A,
where we also show the similarities between this state-dependency and the
explicit state-dependency in the QSP model (2.34). But, in the current work,
the time-rescaling equation (2.29) will be sufficient for our purposes.
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Notice that while the derivation of (2.33) makes sense when considering the
limit of the shape of the probability density functions gnn/τ (t) as they approach
the δ-function δ(t − τ) when n → ∞, it is problematical if one interprets the
distributed DDE (2.31) via the ODE system (2.28) or (2.30) since then the
limiting process would correspond to taking the number of compartments n
to infinity while increasing the rate constants a to infinity also.
Since the system (2.30) corresponds to the Quartino model (2.2) with time
rescaled by (2.26), positivity of solutions is guaranteed by Theorem 2. The
correspondence between the distributed delay system (2.31) and the system
(2.30) ensures positivity of solutions of (2.31) for integer n only, but actually
positivity can be established for all real n > 0. The proof of the positivity of
solutions to (2.30) is given in Theorem 3 in Appendix B.1.
2.3 A QSP model of granulopoiesis and its regulation by G-CSF
As previously mentioned, DDEs are frequently relied upon to model granu-
lopoiesis given the delays inherent to hematopoiesis. Here we focus on the
Quantitative systems pharmacology model of [15], which has been shown to
account for the dynamics of neutrophil production and its negative feedback
relationship with G-CSF–both bound to receptors on the surface of neutrophils
and freely circulating–in a variety of scenarios. The model is written as
d
dt
Q(t) = −(κ(G1(t)) + κδ + β(Q(t)))Q(t)
+AQ(t)β (Q(t− τQ))Q(t− τQ) (2.34a)
d
dt
NR(t) = AN (t)κ(G1(t− τN (t)))Q(t− τN (t)) VNM(G1(t))
VNM(G1(t− τNM(t)))
− (γNR + ϕNR(GBF (t)))NR(t) (2.34b)
d
dt
N(t) = ϕNR(GBF (t))NR(t)− γNN(t), (2.34c)
d
dt
G1(t) = IG(t) +Gprod − krenG1(t) (2.34d)
− k12([NR(t) +N(t)]V −G2(t))G1(t)sG + k21G2(t) (2.34e)
d
dt
G2(t) = −kintG2(t) + k12
(
[NR(t)+N(t)]V−G2(t)
)
G1(t)
sG− k21G2(t)
(2.34f)
Here Q(t) is the concentration of HSCs (106 cells/kg), NR(t) the concentration
of neutrophils in the bone marrow reservoir (109 cells/kg), N(t) the concen-
tration of circulating neutrophils (109 cells/kg), G1(t) the circulating G-CSF
concentration (ng/mL), and G2(t) the bound G-CSF concentration (ng/mL).
Here, and throughout, the superscript h denotes the homeostasis value of a
quantity. The system (2.34) is subject to the initial conditions (ICs) and his-
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tory functions
Q(s) =ϕ1(s) for s ∈ [−τQ, 0]
NR(0) =NR,0
N(0) =N0
G1(s) =ϕ2(s) for s ∈ [−τ, 0]
G2(0) =G2,0,
(2.35)
where ϕ1,2(t) ∈ C0 and
τ = sup
t>0
τN (t). (2.36)
IG(t) models the administration of exogenous G-CSF. As described in [15],
the self-renewal β(Q) and amplification factor AQ(t) of the HSCs are given by
β(Q) = fQ
θ
sQ
2
θ
sQ
2 +Q
sQ
, AQ(t) = A
h
Q = 2e
−γQτQ ,
and the rate at which HSCs differentiate into neutrophil precursors is deter-
mined by the circulating concentration of G-CSF
κ(G1) = κ
h + (κh − κmin)
[
Gsκ1 − (Gh1 )sκ
Gsκ1 + (G
h
1 )
sκ
]
.
The rate at which the neutrophil progenitors proliferate is given by
ηNP (G1(t)) = η
h
NP + (η
h
NP − ηminNP )
bNP
Gh1
(
G1(t)−Gh1
G1(t) + bNP
)
, (2.37)
where τNP days is the time it takes for proliferation. After exiting proliferation,
cells mature with rate
VNM(G1(t)) = 1 + (Vmax − 1)
G1(t)−Gh1
G1(t)−Gh1 + bV
,
where the maximal age of maturing neutrophils is aNM . Given VNM(G1(t)) de-
pends on the circulating concentration of G-CSF, the time it takes neutrophils
to mature satisfies ∫ t
t−τNM(t)
VNM(G1(s))ds = aNM , (2.38)
and the total time for the process of granulopoiesis is then the sum of the time
to completion of each process, given by
τN (t) = τNP + τNM(t).
Maturing neutrophils are assumed to be subject to a constant death rate γNM ,
and their amplification factor AN (t) is given by the integral equation
AN (t) = exp
[∫ t−τNM(t)
t−τN (t)
ηNP (G1(s))ds− γNM τNM(t)
]
. (2.39)
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The fraction of G-CSF bound to neutrophil receptors given by
GBF (t) =
G2(t)
V [NR(t) +N(t)]
∈ [0, 1], GhBF =
Gh2
V [NhR +N
h]
.
regulates the rate with which cells exit the marrow reservoir as
ϕNR(GBF (t)) = ϕ
h
NR + (ϕ
max
NR − ϕhNR)
GBF (t)−GhBF
GBF (t)−GhBF + bG
.
Mature neutrophils die from the marrow reservoir with rate γNR . Cells that
transit into circulation are removed with constant rate γN .
Proofs of the existence, uniqueness, positivity, and boundedness of solutions
to (2.34) are provided in Appendices B.2 and C.
3 Stability Analysis
We now perform stability analyses of the different models derived in the last
section to determine what parameter values, if any, will render an equilibrium
point unstable, most frequently by having sustained oscillations about it. This
is done using a well-established technique, namely linearising about this equi-
librium and then calculating at which parameter values the ensuing charac-
teristic equation will have roots with positive real parts. This same technique
is traditionally applied to systems of ODEs in which case the characteristic
equation is a polynomial.
In general, the characteristic equation associated with an arbitrary distri-
bution is transcendental and possesses an infinite number of roots. As we shall
see, the advantage of an integer-order gamma distribution is to yield a charac-
teristic equation which is also a polynomial, reflecting the fact, mentioned in
Section (2.2.1) that the gamma distribution yields a system of ODEs. In the
context of comparing and contrasting the different models, we obtain a “conti-
nuity” result of sorts as we determine that approximation in distribution does
lead to approximation in stability diagrams (see [4] for a similar continuity
argument).
3.1 Characteristic equations for the Quartino endogenous G-CSF Models
Consider first the generalised Quartino model (2.2). Let
X(t) := (P (t), T1(t), . . . , Tn(t), N(t), G(t))
ᵀ ∈ Rn+3 (3.1)
be the vector of solutions so that (2.2) can be rewritten in vector form as
dX
dt
= F(X), (3.2)
where F(X) represents the right hand side of the Quartino model (2.2). Let
X∗ be an equilibrium of the system (that is that F(X∗) = 0), then define
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Z = X(t) − X∗ and let J(X∗) be the Jacobian of (2.2) evaluated at X∗
(J(X) = dF/dX). Then linearising about X∗ we obtain
dZ
dt
= J(X∗)Z, (3.3)
where nonlinear terms of order O(‖Z‖2) are neglected. Seeking a nontrivial ex-
ponential solution Z(t) = Ceλt of (3.3) with C ∈ Rn+3, a vector of constants,
and λ ∈ C, we obtain the characteristic equation
det(λI− J) = 0, (3.4)
where I ∈ R(n+3)×(n+3) is the identity matrix. Evaluating the determinant
in (3.4) leads to the characteristic equation, which is stated as Eq. (D.2) in
Appendix D.1. This gives a polynomial of degree n+ 3 in λ for the Quartino
model (2.2), and a polynomial of degree 7 if we set n = 4, as in [43]. A steady
state is unstable if any of the roots of this polynomial have positive real part.
The characteristic polynomial for the time rescaled Quartino model (2.30)
is also a polynomial in λ of degree n+ 3, and actually has a simpler form than
the characteristic polynomial for Quartino model (2.2). But to derive this
characteristic polynomial it is convenient to first consider the characteristic
functions of the discrete delay DDE (2.33) and the distributed DDE model
(2.31).
Let Y(t) := (P (t), N(t), G(t))ᵀ denote the vector of solutions of the dis-
crete delay DDE (2.33), and Yτ := Y(t−τ) be the vector of delayed solutions.
Then we can rewrite the the DDE (2.33) as
dY
dt
= F(Y,Yτ ), (3.5)
in vector form. Similar to the ODE case, let F(Y∗,Y∗) = 0 be a generic steady
state. Define the variables Z := Y −Y∗ and Zτ := Yτ −Y∗ and denote the
linearisation matrices of (3.5) computed at (Y,Yτ ) = (Y
∗,Y∗) by A and B.
Linearising (3.5) about Y∗ and using the variables Z and Zτ yields
dZ
dt
= AZ +BZτ . (3.6)
The linearisation matrices A and B from (3.6) are calculated in Appendix D.3.
Seeking a nontrivial exponential solution Z(t) = Ceλt for equation (3.6), with
constant C ∈ R3 and λ ∈ C, we obtain the characteristic equation
det(λI−A− e−λτB) = 0, (3.7)
where I is the identity matrix. Evaluating the determinant in (3.7) gives the
transcendental characteristic equation
λ3 + a2λ
2 + a1λ+ a0 = be
−λτ , (3.8)
where the coefficients a2, a1, a0 and b are computed in Appendix D.3.
20 Daniel Caˆmara De Souza, Morgan Craig et al.
In general equation (3.8) has infinitely many roots, corresponding to the
infinite dimensional nature of DDEs. The treatment of these equations is made
tractable because although there can be infinitely many complex numbers λ
that satisfy (3.8), it is well known that for any real number σ there can only
be finitely many solutions λ with Re(λ) > σ (see for example Lemma 4.2 in
[46]). To determine stability we need to ascertain whether all the roots have
Re(λ) < 0.
Comparing the discrete delay DDE (2.33) with the distributed delay DDE
(2.31), we see that they differ in only one term. Thus the linearisation of the
distributed delay DDE (2.31) follows exactly the steps taken for the discrete
delay DDE (2.33). Then, following MacDonald [34], the characteristic equa-
tion for the distributed DDE (2.31) corresponds to (3.8) with the term e−λτ
replaced by
G(λ) =
∫ ∞
0
e−λugna (u)du =
an
(a+ λ)n
, (3.9)
where G(λ) is the Laplace transform of the gamma probability density func-
tion, and hence we obtain
λ3 + a2λ
2 + a1λ+ a0 − a
nb
(a+ λ)n
= 0, (3.10)
where the coefficients aj and b computed in Appendix D.3 are the same as
those for (3.8). Notice that if b = 0 then (3.8) and (3.10) both reduce to the
same cubic polynomial.
If n is an integer, equation (3.10) is the characteristic equation of both
the distributed DDE (2.31) and the equivalent time-rescaled Quartino ODE
model (2.30). In that case, for b 6= 0, equation (3.10) can be written as
(1 + λ/a)n(λ3 + a2λ
2 + a1λ+ a0)− b = 0, (3.11)
a polynomial of degree n + 3, which can be used to determine the stability
of the steady-states of these models. But since the time rescaling (2.29) is
monotonic this will also determine the stability of the steady-states of the
Quartino model (2.2). Characteristic equations which reduce to polynomials,
such as (3.10) with n an integer, are said to be reducible [34].
The characteristic equation (3.10) is also valid for the distributed DDE
(2.31) when n > 0 is not an integer. For general irrational n, equation (3.10)
can have infinitely many roots, as is the case for the discrete DDE (3.8).
But, if n = p/q is rational, where p and q are co-prime integers then we
observe rather odd behaviour. For an integer m, suppose that n is rational
with n = p/q ∈ (m,m+ 1), which implies that p ∈ (qm, qm+ q). Solutions of
(3.10) with b 6= 0 then satisfy
(1 + λ/a)p(λ3 + a2λ
2 + a1λ+ a0)
q − bq = 0, (3.12)
(though not all solutions of (3.12) will necessarily solve (3.10) if q is even).
Since (3.12) is a polynomial in λ of degree p + 3q, the discrete delay DDE
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(2.31) has at most p+ 3q ∈ (q(m+ 3), q(m+ 4)) characteristic values λ which
satisfy (3.10) when n = p/q is rational.
It is natural to think of the discrete DDE (2.33) as the limit as n → ∞
with a = n/τ of the distributed DDE (2.31), and indeed with a = n/τ we have
(1 + λ/a)n = (1 + λτ/n)n → eλτ as n→∞, (3.13)
so the characteristic equation (3.11) for the distributed DDE approaches the
characteristic equation (3.8) of the discrete DDE as n → ∞. However, if one
considers n varying across the real numbers this is not a smooth limit as n
transitions between the rationals and irrationals. Consequently, even though
the distributed DDE model (2.31) is valid for general real n, most authors,
even when considering the behaviour as n is varied or as n→∞mainly restrict
attention to the case where n is an integer [5,8,34].
3.2 Stability analysis for the Quartino endogenous G-CSF model and related
forms
The generalised Quartino model (2.2), has two steady states. Assuming that
ktr = kP as in (2.4) for the reasons already stated, and considering the model in
the form (3.2) with vector solution X(t) = (P (t), T1(t), . . . , Tn(t), N(t), G(t)) ∈
Rn these are given by
X∗1 = [P, T1, . . . , Tn, N,G] =
[
0, 0, . . . , 0, 0,
kin
ke
]
, (3.14)
X∗2 =
[
kcircN0
ktr
,
kcircN0
a
, . . . ,
kcircN0
a
,N0, G0
]
, (3.15)
where N0 is given by (2.8).
The time-rescaled Quartino model (2.30) has the same steady states X∗1
and X∗2, since a monotonic rescaling of time does not affect equilibria.
The discrete and distributed delay Quartino DDE models (2.31) and (2.33)
have related equilibria, but in fewer space dimensions, since these models do
not include transit compartments. In the Y(t) = (P (t), N(t), G(t)) ∈ R3 no-
tation of (3.5) these are given by
Y∗1 =
[
0, 0,
kin
ke
]
, (3.16)
Y∗2 =
[
kcircN0
ktr
, N0, G0
]
. (3.17)
If n is a positive integer the distributed DDE (2.31) is equivalent to the Quar-
tino model (2.2) and the steady states Y∗1 and Y
∗
2 correspond exactly to X
∗
1
and X∗2 as defined in (3.14) and (3.15) for the appropriate n, and with the
values of Tj following from (2.32). We have the following stability result for
these equilibria.
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Theorem 1 Provided the parameters satisfy the constraints (2.4) and (2.8)
1. For the distributed delay DDE (2.31) and the discrete delay DDE (2.33)
the steady state Y∗1 is locally asymptotically stable if γ < β and unstable if
γ > β, and the steady state Y∗2 is unstable if γ < β.
2. For the Quartino model (2.2) and the time rescaled Quartino model (2.30)
the steady state X∗1 is locally asymptotically stable if γ < β and unstable if
γ > β, and the steady state X∗2 is unstable if γ < β.
Proof At Y∗1 from (D.10) we have b = 0, thus from (3.8) and (3.10) the char-
acteristic equation for both the discrete and distributed DDE models reduces
to
h1(λ) := λ
3 + a2λ
2 + a1λ+ a0 = 0, (3.18)
and the stability of Y∗1 is the same for both models. If γ > β then from (D.10)
we have 0 > a0 = h1(0), while h1(λ) → +∞ as λ → +∞. Hence, by the
intermediate value theorem there exists λ > 0 such that h1(λ) = 0, and thus
the steady state is unstable.
If γ < β from (D.11) we have a2 > 0, a0 > 0 and a2a1 > a0 and it follows
from the Routh-Hurwitz criteria [34] that Re(λ) < 0 for all characteristic roots
of (3.18), and hence Y∗1 is stable.
For the steady state Y∗2 when γ < β equation (D.11) yields a0 = 0, and
b > 0. For the discrete delay DDE (2.33) the characteristic equation reduces
to
h∞2 (λ) := λ
3 + a2λ
2 + a1λ− be−λτ = 0.
Then h∞2 (0) = −b < 0, while h∞2 (λ) → +∞ as λ → +∞, and the interme-
diate value theorem again implies that the steady state is unstable. For the
distributed DDE (2.31) a similar proof shows instability using the character-
istic function (3.11) becomes
hn2 (λ) = (1 + λ/a)
n(λ3 + a2λ
2 + a1λ+ a0)− b,
which has a positive leading coefficient and is negative when λ = 0, so again
the intermediate value theorem shows that the steady state is unstable.
The steady states X∗1 and X
∗
2 of the Quartino model (2.2) have the same
stability as those of the time-rescaled Quartino model (2.30), as the mono-
tonic time-rescaling does not change the stability, though it will change the
values of the characteristic roots. But the time rescaled model (2.30) has its
characteristic roots given by the degree (n + 3) polynomial (3.11) which has
the same roots as the characteristic equation (3.10) of the distributed delay
DDE, and hence X∗j and Y
∗
j have the same stability. uunionsq
For the standard parameters, as given in Table 1, we have γ > β so The-
orem 1 implies that the neutropenic steady states X∗1 and Y
∗
1 are unstable
in all these models. Proving directly that the homeostatic steady states X∗2
and/or Y∗2 are stable when γ > β is difficult, but we can compute the roots
of the characteristic equations, and these are shown in Figure 3. We see that
the homeostatic steady states are indeed stable when γ > β. Moreover the
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Fig. 3: At the steady state X∗2 of the time-rescaled Quartino model (2.30)
and the corresponding steady state Y∗2 of the distributed and discrete delay
models (2.31) and (2.33) with all parameters from Table 1. (Left): Asterisk
for the discrete delay (2.33) characteristic roots that satisfy (3.8), and in gray
transitioning to black as n is increased from 1 to 40 characteristic roots for
the time-rescaled Quartino model (2.30) and the distributed delay DDE (2.31)
which both satisfy (3.11). (Right): Convergence of the real and negative imag-
inary parts of the rightmost characteristic root, which determines stability as
n increases.
characteristic roots for the time-rescaled transit compartment Quartino model
converge to the characteristic roots for the discrete delay DDE as n increases.
Although the steady state is stable for all the models, we see that it becomes
less stable as n increases, with the real part of the characteristic values tending
to increase with n. The phenomenon of loss of stability for fixed delay τ as n
is increased has long been known, but remains an area of active interest [34,
8,5].
In Section 4 we will study how increasing n can make the system more
susceptible to loss of stability through bifurcations. However, here we point
out that the change in stability observed in Theorem 1 depending on whether
γ > β or γ < β is not a bifurcation in the usual sense. When γ = β the model
is degenerate with the progenitor equation reducing to dPdt = 0.
In the proof of Theorem 1 we made use of the relationships between the
different model formulations to greatly simplify the derivation of the stability
results. In particular the simpler forms of the characteristic equation for the
time-rescaled Quartino (2.30) and DDE models (2.31) and (2.33) makes these
much easier to work with. It is nevertheless possible to directly derive stability
results for the Quartino model (2.2) at least for the steady state X∗1, though
the proofs are much more involved. We include those results in Appendix D.2
for completeness.
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3.3 Stability of the QSP model of granulopoiesis
Here we perform the linear stability analysis of the steady states of the QSP
model defined by the DDE system (2.34), without any exogenous G-CSF, i.e.
IG(t) = 0. Similar to Section 3.2, let X(t) := (Q(t), NR(t), N(t), G1(t), G2(t))
ᵀ
be the vector solution of (2.34) and Xσ := X(t − σ) denote a vector of de-
layed solutions. Then the DDE system defining the QSP model (2.34) can be
rewritten in vector form as
dX
dt
= F(X,XτQ ,XτN ,XτNM). (3.19)
Parameters changes to the model lead to different steady states in equa-
tion (3.19). Let the steady state computed at homeostasis be written as Xh ≡
(Qh, NhR , N
h, Gh1 , G
h
2 ), and denote a generic steady state by X
∗ ≡ (Q∗, N∗R , N∗,
G∗1, G
∗
2).
To linearize (3.19) around a steady state X∗ we define the variables τ(t) =
τN (t)− t and u = s+ τ(t) to rewrite the amplification factor (2.39) as
AN (t) = exp
[∫ τNP
0
ηNP (G1(u− τ(t)))du− γNM τNM(t)
]
. (3.20)
Thus we approximate the amplification factor (3.20) through the linearisation
of the proliferation function (2.37) given by
ηNP (G1) = ηNP (G
∗
1) + η
′
NP (G
∗
1)(G1 −G∗1) +O(|G1 −G∗1|2), (3.21)
where η′NP ≡ dηNP /dG1. Further, since it does not affect the local stability of
the steady state [12], we freeze the state-dependent delay at its steady state
value
τNM(t) = τ
∗
NM. (3.22)
Using (3.21) and (3.22) together with the distributed delay variable defined
by
G˜1(t) :=
∫ τNP
0
G1(u− τ(t))
τNP
du,
equation (3.20) becomes
A˜N (t) = exp
[
η∗NP τNP − γNM τ∗NM + η′NP (G∗1)τNP (G˜1(t)−G∗1)
]
. (3.23)
As a consequence of the approximation in (3.23), we can rewrite (3.19) as
dX
dt
= f(X,XτQ ,XτN ,XτNM, X˜), (3.24)
where
X˜(t) :=
∫ τNP
0
X(u− τ(t))
τNP
du.
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Let X∗ be a generic steady state of (3.24), defined by f(X∗,X∗,X∗,X∗,X∗)
= 0. Define the variables Z := X − X∗, Zσ := Xσ − X∗ and Z˜ := X˜ − X∗
and denote the linearisation matrices of (3.24) with regards to X, XτQ , XτN ,
XτNM, Xτ and computed at X
∗, respectively by A, B, . . ., E. Linearising (3.5)
about X∗ and using the variables Z, Zσ and Z˜ yields
dZ
dt
= AZ +BZτQ + CZτN +DZτNM + EZ˜. (3.25)
The linearisation matrices A, B, . . ., E from (3.25) are computed in Ap-
pendix D.4. Seeking a nontrivial exponential solution Z(t) = Ceλt for equation
(3.25), with constant C ∈ R5 and λ ∈ C, we obtain the characteristic equation
det(λI−A− e−λτQB− e−λτ∗NC− e−λτ∗NMD− f(λ)E) = 0, (3.26)
where I is the identity matrix and
f(λ) :=
(eλτNP − 1)
λτNP e
λτ∗N
=
e−λτ
∗
NM − e−λτ∗N
λτNP
.
For λ = reiθ, with r, θ ∈ R, we have limr→0 f(reiθ) = 1. We rearrange equa-
tion (3.26) in the form det(F) = 0. To calculate the matrix F, with terms Fij
for i, j = {1, 2, . . . , 5}, note that some terms of the linearisation matrices are
symmetric while others are antisymmetric, namely A43 = A42, A52 = −A42,
A53 = −A42, A35 = −A25, and D24 = −A24 (see Appendix D.4). Using this
fact, we can then compute the terms
F11(λ) = A11 − λ+B11e−λτQ , Fii(λ) = Aii − λ for i = 2, 3, 4, 5,
F21(λ) = C21e
−λτ∗N , F24(λ) = A24(1− e−λτ
∗
NM) + C24e
−λτ∗N + E24f(λ),
and write the matrix F as
F =

F11(λ) 0 0 A12 0
F21(λ) F22(λ) A23 F24(λ) A25
0 A32 F33(λ) 0 −A25
0 A42 A42 F44(λ) A45
0 −A42 −A42 A54 F55(λ)
 .
Defining the constants
K1 = −A45A54, K2 = −A42A25, K3 = −A42A25A54,
K4 = A42A25, K5 = −A32A23, K6 = (A23 −A32)A25A42,
K7 = A42A25A54, K8 = [A32(A23A45 −A42A25) +A42A23A25]A54,
K9 = −A42A45, K10 = A32A42, K11 = A32A42A45,
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and the functions
ρ(λ) = F22(λ)[F33(λ)F44(λ)F55(λ) +K1F33(λ) +K2F44(λ) +K3] +
F44(λ)[K4F33(λ) +K5F55(λ) +K6] +K7F33(λ) +K8 +
F24(λ)[K9F33(λ) +K10F55(λ)−A42F33(λ)F55(λ) +K11],
ψ(λ) = F21(λ)[A42F33(λ)F55(λ)−K9F33 −K10F55(λ)−K11]A12,
the characteristic equation det(F) = 0 becomes
F11(λ)ρ(λ) + ψ(λ) = 0. (3.27)
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Fig. 4: Roots of the characteristic equation (3.27) of the QSP granulopoiesis
model (2.34) evaluated at the homeostasis steady state Xh all have negative
real part in the complex plane.
The solutions λ ∈ C to (3.27), the characteristic roots, determine the sta-
bility of the steady state X∗ from (3.19)/(3.25). To evaluate the stability nu-
merically, we write λ = σ+ iω, with σ ∈ R and ω ∈ R, and then compute the
roots of (3.27) in the (σ, ω)-plane using the Matlab subroutine fsolve [38]. As
illustrated in Figure 4, at homeostasis all the characteristic roots λ have nega-
tive real part, and so the homeostatic steady state Xh = (Qh, NhR , N
h, Gh1 , G
h
2 ),
defined by F(Xh,Xh,Xh,Xh) = 0 in (3.19) is locally asymptotically stable.
4 Bifurcation studies
Bifurcation analysis, or the study of the qualitative changes to the behaviour
of a system given a change to parameter values, is a fundamental dynamical
systems concept [39]. Accordingly, studying bifurcation points can be a power-
ful tool in the life sciences to shed light on underlying parameter relationships
and better understand the robustness of a system with regards to stability.
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Historically, bifurcation analysis has been applied to study hematological
pathologies and has provided valuable insight into the origins of disorders like
cyclic neutropenia, a disease associated with dangerously low neutrophil counts
and mouth blistering [16] where a patient’s ANCs oscillate with a period of
around 21 days. These oscillations have been shown to correspond to a peri-
odic orbit that appears through a loss of stability after the system undergoes
a Hopf bifurcation [10,20]. In the following sections, we perform bifurcation
analyses on the equivalent forms of the Quartino endogenous G-CSF model
and the QSP granulopoiesis model (2.34) to ascertain how changing parame-
ter values modify the stability of each system, giving insight into the potential
effects of PK variability on a physiological system and helping to understand
pathophysiology of diseases.
4.1 Bifurcation in the equivalent expressions of the Quartino endogenous
G-CSF model
We begin by investigating whether parameter changes in the equivalent expres-
sions of the Quartino endogenous G-CSF model can lead their steady states
X∗2 and Y
∗
2 given by (3.15) and (3.17), respectively, to lose stability. For this,
we let λ = σ + iω, where σ ∈ R and ω ∈ R, and computed the roots of the
characteristic equations (D.6), (3.8) and (3.11) in the (σ, ω)-plane using the
Matlab subroutines roots and fsolve [38].
We saw in Section 3.2 that the homeostasis steady states X∗2 and Y
∗
2 are
locally asymptotically stable in all the versions of the Quartino model that we
consider, and that the models are degenerate when β = γ, consequently here
we will study the bifurcations that occur as parameters are varied from their
homeostasis values with γ > β.
We begin by studying the Quartino model (2.2) starting from parameters
used in [43], so n = 4, a = ktr and all the other parameters as in Table 1.
We observed that changes to γ, the parameter relating the feedback of circu-
lating G-CSF concentrations on the proliferating pool, and a, the transit rate
between maturation compartments, can lead to a loss of stability giving rise
to a periodic orbit via a Hopf bifurcation. Table 2 summarises the parameter
pair values (γ, a) necessary to induce such a loss in stability in X∗2, and the
resulting period of the emerging periodic orbits.
If we let γ be the bifurcation parameter and keep the remaining parameters
at their homeostasis values (see Table 1), there is a Hopf bifurcation point at
γ = 0.86766. We verified numerically that X∗2 is locally asymptotically stable
for β < γ < 0.86766 and unstable if γ > 0.86766. Of particular interest, as re-
flected in the bolded row of Table 2, we found a periodic orbit characteristic of
cyclical neutropenia [16]. Using the relation a = n/MMT with n = 4 gives the
value MMT= 123.33 hours, which is close to the mean maturation time of 133
hours for a patient under chemotherapy treatment reported by Quartino [43].
In Figure 5 (left) we show the Hopf bifurcation curve for X∗2 on parameter
space (a, γ) for the Quartino model (2.2). The steady state is stable in the
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region below the Hopf curve and unstable otherwise. In Figure 5 (right) we
see that increasing γ for small values of the transit rate parameter n lead to
solutions with long period.
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Fig. 5: Hopf bifurcation curve for X∗2 on parameter space (a, γ) (Left) and the
respective period (in days) as function of a (Right) for the Quartino model
(2.2). The remaining parameters are as in Table 1 and the diamond dot cor-
respond to a at its homeostasis value 0.03759 hours−1.
γ (-) a (hours−1) τ (hours) Period (days)
0.87851 0.03831 104.4 18.00
0.86766 0.03759 106.41 18.32
0.78911 0.03243 123.33 21.0
Table 2: Hopf bifurcation points for varying γ, a, and τ for X∗2 computed as
in Figure 5, Values highlighted in bold correspond to periods characteristic of
patients with cyclic neutropenia.
In the same vein, we also computed bifurcation points for the equilibrium
X∗2 of distributed DDE model (2.31) using the characteristic equation (3.11)
with n = 4. As expected, given that the this model is simply a time-rescaling
of the Quartino model (2.2) we obtain the same bifurcation points shown in
Table 2.
In Figure 6 (left) we show the Hopf bifurcation curve for Y∗2 on parameter
space (n, γ) for the distributed DDE model (2.31). The steady state is stable
in the region below the Hopf curve and unstable otherwise. Increasing n lead
to γ and the period of the Hopf bifurcation converge to the bifurcation point
of the discrete DDE model (2.33) shown in the bolded row of Table 4.
Table 4 reports bifurcation points computed for the steady state Y∗2 of the
discrete DDE model (2.33) using the characteristic equation (3.8). Comparing
the second rows of Tables 2 and 4, we note that the region of stability for the
discrete DDE model β < γ < 0.69754 is smaller than that of the distributed
DDE with n = 4, and of the equivalent ODE Quartino model β < γ < 0.86766.
Transit and lifespan in neutrophil production: implications for drug intervention 29
γ (-) n (-) Period (days)
4.61186 1 7.767
1.69292 1.5 13.53
1.21571 2 15.95
0.90252 3.5 18.08
0.86766 4 18.32
0.75312 10 18.98
0.72367 20 19.08
0.71461 30 19.09
0.71021 40 19.10
0.69754 “∞” 19.11
Table 3: Hopf bifurcation points for varying γ and n for Y∗2 computed as in
Table 6 but considering the characteristic equation of the distributed DDE
model (3.11). The other parameters were fixed at their homeostasis values
given in Table 1. The last row corresponds to the discrete delay case.
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Fig. 6: Hopf bifurcation curve for Y∗2 on parameter space (n, γ) (Left) and the
respective period (in days) as function of n (Right) for the distributed DDE
model (2.31). The other parameters are as in Table 1 and the diamond dot
correspond to n at its homeostasis value 4. The straight lines correspond to
the bifurcation point γ and its respective period for the discrete DDE model
with other parameters at their homeostasis values.
Furthermore, we verified that in the limit n→∞ with a = n/τ or a = (n+1)/τ
and holding τ fixed, the characteristic roots of the distributed DDE model
(3.11) converge to the roots of the discrete DDE model (3.8) since (3.11)
approaches to (3.8) when n→∞.
γ (-) τ (hours) Period (days)
0.72631 99.8 18.00
0.69754 106.41 19.11
0.65534 117.75 21.00
Table 4: Hopf bifurcation points for varying γ and τ for Y∗2 computed as in
Table 6 but considering the characteristic equation of the discrete DDE model
(3.8). The other parameters were fixed at their homeostasis values given in
Table 1.
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In Figure 7 (left) we show the Hopf bifurcation curve for Y∗2 on parameter
space (τ, γ) for the discrete DDE model (2.33). The steady state is stable in
the region below the Hopf curve and unstable otherwise. In Figure 7 (right)
we see that there is an approximate linear relation between the period of the
limit cycles and the mean value of the distributed delay τ for along all values
of γ.
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Fig. 7: Hopf bifurcation curve for Y∗2 on parameter space (τ, γ) (Left) and
the respective period (in days) as function of τ (Right) for the discrete DDE
model (2.33). Squares represent integer numbers n. The remaining parameters
are as in Table 1 and the diamond dot correspond to τ at its homeostasis value
106.41 hours.
4.2 Bifurcations in the QSP model of granulopoiesis
We also studied whether parameter changes can lead the steady state X∗
of system (2.34) to lose stability. We observed that changes in parameters
related to proliferation and maturation lead to a loss of stability via a Hopf
bifurcation, as reflected in Table 5. Inversely, we further verified the stability
of the steady state when the half-maximal neutrophil proliferation constant
satisfies bNP ∈ [bNP × 10−3, bNP × 103], the rate of maturing neutrophil death
satisfies γNM ∈ [γNM × 10−2, γNM × 102], and the neutrophil apoptosis rate in
the bone marrow reservoir satisfies γNR ∈ [γNR × 10−2, γNR × 102].
We further investigated whether varying pairs of parameters in tandem
could lead the steady state to lose stability via a Hopf bifurcation, as reflected
in Table 6. An additional Hopf bifurcation point leading to an orbit of period
of 20.94 days was observed by changing four parameters simultaneously: ηhNP =
1.7 days−1; bNP = 2.0 ng/mL; η
min
NP
= 1.3 days−1; and τNP = 6.1 days.
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Parameter (units) Homeostasis Value Hopf Bifurcation Period (days)
γQ (days
−1) 0.1 0.22791 36.69
ηhNP
(days−1) 1.6647 7.4 60.31
ηminNP
(days−1) 1.4060 0.81 25.86
Vmax (-) 7.8669 93 5.20
bV (ng/mL) 0.24610 0.0184 5.20
Table 5: For each line the Hopf bifurcation point were computed changing
the respective parameter and following the solution λ of Eq. (3.27) in the
(σ, ω)-plane numerically, the period was estimated by 2pi/ω and the parameters
values at homeostasis were obtained from [15].
Parameters (units) Hopf Bifurcation Period (days)
(Vmax, bV ) (-,ng/mL) (30, 7.8) 5.20
(Vmax, bV ) (-,ng/mL) (61, 16.1) 5.20
(bNP , η
min
NP
) (ng/mL,days−1) (0.065, 1.1) 25.86
(ηhNP
, ηminNP
) (days−1,ng/mL) (2, 1.1) 32.58
Table 6: For each line the Hopf bifurcation point were computed changing
the respective pair of parameters and following the solution λ of Eq. (3.27)
in the (σ, ω)-plane numerically, the period was estimated by 2pi/ω and the
parameters values at homeostasis were obtained from [15].
5 The impact of stability and bifurcations on PK/PD
considerations
In the PK/PD context, sensitivity analysis is frequently applied to investi-
gate the impact of parameters variability on the system’s output. There the
goal is to understand how predictions (outputs) change given changes to ini-
tial values (inputs). Still, when evaluating treatments, one may wonder how
small changes to parameters affect the qualitative (e.g. existence and stability
of equilibria, etc.) behaviour of the model. For example, if we have a priori
information about a PK parameter’s variability and this parameter helps de-
termine the model’s stability, bifurcation analysis can help to assess whether
small changes within the range of the measured variability can bring about
serious unintended shifts in the physiological system. Put another way, how
are parameters changing when the system shifts stability or becomes unstable?
Bifurcation analysis is rarely used in conventional PK/PD analyses, however
the study of qualitative model behaviour is becoming increasingly recognised
as an important tool for drug development [3,23]. The potential impact of vari-
ability in PK parameters on the dynamics of the governing equations, which
correspond to the PD aspects, is multifaceted. Within pharmacometrics, var-
ious situations must therefore be considered when assessing which (and how)
parameters are susceptible to generating bifurcations when their values change.
In the simplest case, for physiological or drug parameters not influenced
by drug concentration, no bifurcation can be generated through any PK vari-
ability. Examples of such parameters could include the maximal achievable
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response in an Emax model or a zero-order endogenous production rate. In
that vein, we observe that in the Quartino model, the bifurcation point for γ
is not likely to be reached by realistic variations in G-CSF concentrations.
More familiar to the pharmacometrician is the case where different parame-
ters values associated with specific cohorts and/or patient subpopulations cor-
respond to individual states in the dynamical system. Here bifurcation analysis
is analogous to Population-PK (Pop-PK) covariate analysis techniques used to
separate and determine Pop-PK models for each subgroup. From this covari-
ate analysis, one infers that for each state, there is a particular PK/PD model
for which the (between subject) variability has been explained. Accordingly,
Pop-PK covariate studies examine the impact of between subject variability is
readily accounted for during the process of building a Pop-PK model. In the
same way, bifurcation analysis of mathematical models helps to ascertain how
changes to (variability in) model parameters affect the stable state. Of note,
in the most complex case, where the parameters of a dynamical system are af-
fected by PKs (which can also vary during therapy), within subject variability
in PK is an important factor in determining model stability and a case-by-case
model analysis must be carried out.
The impact of interindividual variability (IIV) is also an open question
when considering the time-rescaled Quartino (2.30) and discrete delay (2.33)
models. Since the discrete delay model is the equivalent to taking n to infinity
in (2.30), we investigated whether there would be altered behaviour due to IIV
with increases in n. We began by generating 30 virtual patients using the doc-
etaxel Pop-PK model of Bruno [7] and set Edrug=SlopeCdoc, as in [43], where
Cdoc is the concentration of docetaxel in the central compartment. Using the
same individual patient values for the generalised and time-rescaled Quartino
models, we verified that solutions to (2.2) were identical as the solutions to
(2.30) when the latter were rescaled according to (2.29) (not shown). We pro-
ceeded to compare the full Pop-PK predictions of (2.2) for these 30 virtual
patients when n = 4 and n = 10. In Figure 8, increases to n are not signifi-
cantly affected by the inclusion of IIV, though increases to n decidedly impact
on the distribution of solutions. Given these results and to better visualise the
impact of increasing n, we then compared the predictions of (2.2) to (2.33)
(the case of infinite n) using only the typical parameter estimates. As seen in
Figure 9, in the limit n → ∞, solutions to the generalised Quartino model
(and equivalently, the time-rescaled Quartino and distributed delay models)
converge to that of the discrete delay. Further, as n increases, so too does the
dimension of the resulting ODE system for (2.2), which is not the case for the
3 equations of (2.33), thereby encouraging the use of a delay model to speed
up simulation time. It should be noted that in all simulations described in this
section, due to the misspecification of MMT as MMT=(n+1)/ktr, to compare
directly with the results of [43] ktr = kP were fixed to the value in Table 1,
MMT was taken to be 133 hours, and τ was recalculate as τ = (4/5)MMT,
with a = n/τ .
The analysis and results of Section 3.3 indicate the interest of perform-
ing stability and bifurcation studies in the pharmaceutical sciences setting.
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Fig. 8: Impact of IIV on the Quartino model (2.2) and its equivalent forms
(2.30) and (2.31) for two different values of n. PopPK parameters for 30 vir-
tual patients were generated following [7] and used as inputs to (2.2). Solid
blue lines: individual predictions; black dotted-dashed lines: 10th and 90th
percentiles of predictions; red dashed lines: median prediction.
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Fig. 9: Neutrophil and G-CSF concentrations from the generalised Quartino
model (2.2) and the equivalent time-rescaled discrete delay model (2.33) for
increasing values of n. Since the discrete delay model (2.33) is expressed in
the time-rescaled tˆ(t), we inverted (2.29) and mapped the simulated solution
back to t to directly compare to (2.2). Dashed line: solution of discrete delay.
Through sensitivity analysis, we have previously concluded that models con-
structed from first-principles, such as (2.34), are robust to PKs by “sufficiently”
accounting for the system’s physiological mechanisms [14]. Thus average PK
parameters without reference to the full Pop-PK model are reliably predictive
of the behaviour of such physiological models. Here we extend our previous
work to study how PK variability (variations in G-CSF concentrations) affect
the stable states of the PD (physiological) system.
The granulopoietic system is indeed very robust around homeostatic pa-
rameter values. An increase in G-CSF concentrations corresponds to a decrease
in the value of γQ, and, from Table 5, destabilisation of this equilibrium can
only occur when γq > γ
h
Q, and thus such changes preserve homeostasis. With
regard to changes in the proliferative progenitor compartment, either by vari-
ations in the parameters ηhNP or bv, physiologically realistic scenarios preclude
reaching the bifurcation values: for example, in the case of ηhNP , artificial re-
moval of G-CSF from the body would be required.
6 Discussion
Mathematical pharmacology, defined as the study of mathematical approaches
to pharmacological processes, is increasingly recognised as a quantitative method-
ology critical to understanding pharmaceutical treatments and their efficacy
while simultaneously raising compelling mathematical problems [25]. Using
granulopoiesis as a backdrop, in the present paper we have examined the con-
nections between the familiar PK/PD model formalism originally proposed
by Friberg [21] and adapted by Quartino [43] and a discrete delay model of
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neutrophil production, connected via a distributed delay model. Crucially, we
have shown how the stability of each model can be studied straightforwardly
via this latter distributed delay model, underlining the advantage of being able
to transfer between these equivalent expressions and motivating the present
analysis. We examined the impact of the inclusion of IIV on the solutions
to each of the models, and determined that variations are driven through in-
creases to n rather than the presence of variability; as n→∞, solutions of the
generalised (time-rescaled) Quartino transit compartment model converge to
that of the time-rescaled discrete DDE model. Last, using our previously pub-
lished QSP model of the negative feedback relationship between granulopoiesis
and G-CSF, we have identified several Hopf bifurcations through bifurcation
analysis, a technique not commonly applied in the classical PK/PD analyses,
and reviewed the impact the interpretation of such bifurcations can have on
our understanding of pharmacological systems when used in concert with more
common sensitivity and variability analyses. We would like to highlight two
results in particular. First, the distributed delay model (2.31) exhibits wider
regions of stability around the steady state Y∗2 as compared to the discrete
DDE model (2.33), consistent with the result that “distributed delays are in-
herently more stable than the same system with discrete delays” [8]. Second,
we identified Hopf bifurcations in the distributed and discrete delay forms of
the Quartino model with periods corresponding to those in cyclic neutropenic
patients by varying the feedback parameter γ and the delay τ , demonstrat-
ing how bifurcation analyses can be applied in mathematical pharmacology to
understand the pathogenesis towards diseases.
Perhaps the most immediately consequential conclusion drawn here is the
incorrect definition of the mean transit/maturation time in the original and
subsequent applications of the Friberg model. As previously mentioned, by
setting kP = a = ktr withG(t) = G0, the MTT(MMT) was originally expressed
as (n+1)/ktr. However, we have shown that the mean delay of the distributed
delay model is constant and instead given by τ = n/a (which, when a = ktr is
then clearly given by n/ktr). Thus it is mathematically incorrect to set MMT=
(n+1)/a as it treats the proliferative pool as an additional transit compartment
and this formulation cannot be recovered via the linear chain technique. The
generalised Quartino model (2.2) explicitly decouples the maturation time
and the production rate of cells to eliminate this problem. Additionally, we
highlighted the mathematical issue presented when a is non-constant, as in
[43], to the derivation (2.14), which is essential to the linear chain technique to
recover the correct ODE formulation from the distributed delay model (2.26).
Further, since, in [21] and its various extensions and applications, the pa-
rameter ktr is determined via the MMT, the mean maturation time is fit and
then the rate of transit through each compartment is determined via the equa-
tion MMT= (n+ 1)/ktr. This leads to disparate estimates for the maturation
process, ranging, for example, from 102 hours (n = 6) in [42] to 210 hours
(n = 4) in [43]. Physiological labelling studies report a much narrower range
of maturation times (6.4 days in [40] and 6.9 days in [17], for example). Thus,
allowing the MMT to vary widely is not physiologically consistent and fur-
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ther introduces additional mathematical difficulties since, in general, τ = n/a,
where a is not necessarily equal to ktr nor kP.
We therefore emphasise that this work provides further motivation to sys-
tematically incorporate, from first principles, the physiological architecture
yielding the proper mathematical formulation of pharmacological models.
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Appendices
A Time Rescaling of Quartino Model
Here we show how the time rescaling (2.29) we applied to the generalised Quartino model
(2.2) relates to the state-dependent delays that are used in the QSP granulopoiesis model
(2.34).
For the Friberg model (2.1) we have average maturation delay τ given by τ = n/a.
Hence
n = aτ =
∫ t
t−τ
ads.
For the Quartino model (2.2) the maturation rate a is replaced by a(G/G0)β and hence the
time-dependent maturation delay α(t) for this model is given by
n =
∫ t
t−α(t)
a
(
G(s)
G0
)β
ds.
Thus the mean maturation time τ for the time-rescaled Quartino model (2.30) is related to
α(t) by
τ =
n
a
=
∫ t
t−α(t)
(
G(s)
G0
)β
ds. (A.1)
Equation (A.1) defines α(t) by a threshold condition. This is completely analogous to the
threshold condition (2.38) used to define the state-dependent delay τNM(t) in the QSP model
(2.34).
Differentiating (A.1) using Leibniz rule we obtain an expression for the evolution of α(t)
as
0 =
(
G(t)
G0
)β
−
(
1− dα
dt
)(G(t− α(t))
G0
)β
,
which can be rewritten as
dα
dt
= 1−
(
G(t)
G(t− α(t))
)β
, (A.2)
and determines the evolution of α(t). An analogous expression was derived in Craig [15] for
the evolution of τNM(t) in the QSP model (2.34).
B Positivity of Solutions
We show positivity of the solutions to the models considered in the paper.
B.1 Positivity of solutions to the Quartino endogenous G-CSF model
Consider the generalised Quartino model (2.2).
Lemma 1 Assume that the parameters in (2.2) are strictly positive and that G(0) > 0.
i) Then G(t) > 0 for all time t > 0.
ii) If N(t) > 0 for t ∈ [0, tN] then G(t) 6 max{kin/ke, G(0)} for all t ∈ [0, tN].
Proof i) Either G(0) > 0 or G(0) = 0 and dG
dt
(0) = kin > 0. In both cases G(t) > 0 for
t ∈ (0, ε) for some ε > 0. Assume, for contradiction, that there exists tG > 0 such that
G(tG) = 0 but G(t) > 0 for t ∈ (0, tG). Since G is decreasing at t = tG this implies that
dG
dt
(tG) 6 0. But this is contradicted by (2.2) which implies that dGdt (tG) = kin > 0 if
G(tG) = 0. Thus there exists no such that time tG, and hence G(t) > 0 for all t > 0. uunionsq
ii) For t ∈ [0, tN] we have dGdt 6 kin − keG, and hence dGdt < 0 if G(t) > kin/ke. The result
follows. uunionsq
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Lemma 2 Assume that the parameters in (2.2) are strictly positive, and that the initial
conditions satisfy P (0) > 0 and G(0) > 0. Furthermore, assume that there exists tN > 0
such that N(t) > 0 for t ∈ [0, tN]. Then P (t) > 0 for all time t ∈ [0, tN].
Proof By Lemma 1 for t ∈ [0, tN] we have 0 6 G(t) 6 M = max{kin/ke, G(0)}. Thus from
(2.2) we have
dP
dt
> −ktr
(
M
G0
)β
P (t),
which (using the continuous Gronwall lemma) implies that
P (t) > P (0) exp
[
−ktrt
(
M
G0
)β]
> 0, t ∈ [0, tN]. uunionsq
Lemma 3 Assume that the parameters in (2.2) are strictly positive, and that the initial
conditions satisfy P (0) > 0, G(0) > 0 and Tj(0) > 0 for j = 1, 2, . . . , n. Then there exists
ε > 0 such that Tj(t) > 0 for all time t ∈ (0, ε) for all j = 1, 2, . . . , n. Furthermore, if there
exists tN > 0 such that N(t) > 0 for t ∈ [0, tN] then Tj(t) > 0 for all time t ∈ (0, tN] for all
j = 1, 2, . . . , n.
Proof We proceed by induction on j. For j = 1, either (i) T1(0) > 0 and G(0) > 0, or (ii)
T1(0) = 0 and G(0) > 0, or (iii) T1(0) = G(0) = 0. In case (ii)
dT1
dt
(0) = ktr
(
G(0)
G0
)β
P (0) >
0, while in case (iii) T1(0) =
dT1
dt
(0) = 0.
For all three cases, P (0) > 0 implies that that there exists ε > 0 such that P (t) > 0
for t ∈ (0, ε). Lemma 1 ensures also that G(t) > 0 for t ∈ (0, ε). But now, for t ∈ (0, ε) if
T1(t) 6 0 we have the strict inequality
dT1
dt
(t) =
(
G(t)
G0
)β
(ktrP (t)− aT1(t)) > 0.
Thus if there exists t1 ∈ (0, ε) such that T1(t1) 6 0 then ddtT1(t) > 0 for all t < t1 and
therefore T1(0) < 0, which contradicts the initial condition. Hence there exists no such time
t1, and so T1(t) > 0 for t ∈ (0, ε).
For general j, it is shown that Tj(t) > 0 for t ∈ (0, ε) similarly. The positivity of G(t) > 0
and Tj−1(t) > 0 for t ∈ (0, ε) along with the strict inequality
dTj
dt
(t) = a
(
G(t)
G0
)β
(Tj−1(t)− Tj(t)) > 0,
for all t ∈ (0, ε) if Tj(t) 6 0 similarly ensures that actually Tj(t) > 0 for t ∈ (0, ε), which
establishes the result for any finite n.
Now, from Lemmas 1 and 2, if there exists tN > 0 such that N(t) > 0 for t ∈ [0, tN]
then P (t) > 0 for all time t ∈ [0, tN] and 0 6 G(t) 6M = max{kin/ke, G(0)}. Now we have
T1(t) > 0 for t ∈ (0, ε) and for j = 1
dTj
dt
> −a
(
M
G0
)β
Tj(t), (B.1)
which, similar to the proof of Lemma 2, implies T1 > 0 for all t ∈ (0, tN]. But if Tj−1(t) > 0
for all t ∈ (0, tN] then Tj(t) > 0 satisfies (B.1) and it follows by induction that Tj(t) > 0 for
all t ∈ (0, tN] for j = 1, . . . , n if N(t) > 0 for t ∈ [0, tN]. uunionsq
Theorem 2 Assume that the parameters in (2.2) are strictly positive, and that the initial
conditions satisfy P (0) > 0, G(0) > 0, N(0) > 0 and Tj(0) > 0 for j = 1, 2, . . . , n. Then
P (t) > 0, 0 < G(t) 6 M = max{kin/ke, G(0)}, N(t) > 0 and Tj(t) > 0 for j = 1, 2, . . . , n
for all t > 0.
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Proof Lemma 1 implies that G(t) > 0 for all t > 0. While P (0) > 0 and Lemma 3 imply
that P (t) > 0 and Tj(t) > 0 for j = 1, 2, . . . , n for t ∈ (0, ε).
Now similar to the proof of Lemma 3,
dN
dt
(t) = a
(
G(t)
G0
)β
Tn(t)− kcircN(t) > 0, if N(t) 6 0,
implies thatN(t) > 0 for t ∈ (0, ε). Then whileN(t) > 0, we haveG(t) 6M = max{kin/ke, G(0)}
and
dN
dt
(t) > −kcircN(t).
But this last inequality implies that N(t) > 0 for all t > 0. It follows from Lemmas 1, 2
and 3 that G(t) 6M = max{kin/ke, G(0)}, P (t) > 0, and Tj(t) > 0 for j = 1, . . . , n for all
t > 0. uunionsq
Although an essential part of the solution positivity proofs in this section was to show
that solutions decay with at most a bounded linear rate for general parameters, these are
not the dynamics that we actually expect to observe. For normal individuals/subjects we
should have γ > β (as is the case for the parameters in Table 1), in which case when G(t) is
sufficiently large dP
dt
is positive, as is required for the feedback loops to function effectively.
Since the Quartino model (2.2) is equivalent to the time-rescaled Quartino model (2.30)
and the distributed DDE (2.31), positivity of solutions to those models follows directly from
Theorem 2 (it is important to note that tˆ(t) > 0 for all t > 0 follows from (2.29) and the
positivity of G(t)). However, this only establishes positivity of solutions for the distributed
DDE (2.31) when n is an integer. When can show positivity directly for both the distributed
DDE (2.31) for general real n and also for the discrete DDE (2.33).
Theorem 3 Assume that the parameters in distributed delay DDE (2.31) or the discrete
delay DDE (2.33) are strictly positive, and that the initial conditions satisfy G(0) > 0,
N(0) > 0, and P (tˆ) = ϕ(tˆ) for tˆ 6 0 where ϕ is continuous and P (0) = ϕ(0) > 0. Then
Then P (tˆ) > 0 and 0 < G(tˆ) 6M = max{kin/ke, G(0)} for all tˆ > 0. Finally N(tˆ) > 0 for
all tˆ > 0 for the system (2.31), and for all tˆ τ for the system (2.33).
Proof The proof uses similar ideas to the proof of Theorem 2, so we just outline the details
here. We have P (0) > 0, and similar to the proof of Lemma 2 the rate of decrease of P (tˆ)
is bounded so P (tˆ) > 0 for all tˆ > 0. But now for (2.31), the positivity of P ensures that
d
dt
N > 0 if N = 0, which ensures that N(tˆ) > 0 for all tˆ > 0. For the model (2.33),
P (tˆ− τ) > 0 for tˆ > τ leads to the positivity of N(tˆ) > 0 for all tˆ > τ . Finally the bounds
on G are derived similarly to Lemma 1. uunionsq
B.2 Positivity of solutions to the QSP granulopoiesis model
Consider the QSP granulopoiesis model (2.34). Using the constraints listed in (C.1) and
setting
GBF =
G2(t)
V [NR(t) +N(t)]
,
yields
V (G1(t)) > 0 if G1(t) > 0
ϕNR (GBF (t)) > 0 if GBF (t) > 0
κ(G1(t)) > 0 if G1(t) > 0
β(Q(t)) > 0 if Q(t) > 0.
(B.2)
Lemma 4 Consider the initial value problem P, given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35), with G1,0 + G2,0 > 0. Assume that Gprod, kren and
kint are positive constants and set β = max{kren, kint}. Then
G1(t) +G2(t) > Ke−βt with K > 0 ∀t > 0.
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Proof A simple calculation shows
d
dt
[G1(t) +G2(t)] = Gprod − (krenG1(t) + kintG2(t))
> Gprod − β(G1(t) +G2(t)).
Multiplying by eβt and rearranging gives
d
dt
[(G1(t) +G2(t))e
βt] > Gprodeβt.
Integrating the inequality from 0 to t yields
G1(t) +G2(t) >
Gprod
β
(1− 1
eβt
) + [G1,0 +G2,0]e
−βt > [G1,0 +G2,0]e−βt.
Taking K = [G1,0 +G2,0] yields the claim. uunionsq
Rearranging the bound of Lemma 4 gives:
G2(t) > Ke−βt −G1(t). (B.3)
Lemma 5 Consider the initial value problem, P, given equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35), with G1,0 + G2,0 > 0 and G1,0 > 0. Assume that
Gprod, kren, k21 and kint are strictly positive constants. Then, G1(t) > 0 for all t > 0.
Proof Assume, for contradiction, that there exists a time s > 0 such that G1(s) < 0. As G1
is a solution of the differential equation, it is continuously differentiable. By the IVT, there
must exist a time T ∗ such that G1(T ∗) = 0 with s > T ∗. Using (B.3), at t = T ∗:
d
dt
G1(t)|t=T∗ = Gprod + k21G2(T ∗)
> Gprod + k21(Ke−2βT
∗ −G1(T ∗))
> Gprod > 0.
The Mean Value Theorem (MVT) yields a contradiction to G1(s) < 0. uunionsq
Lemma 6 Consider the initial value problem P, equations (2.34a)– (2.34f) and the ICs
and histories given in (2.35), with G1,0+G2,0 > 0, G1,0 > 0 and ϕ1(s) > 0 for s ∈ [−τQ, 0]
with ϕ1(s∗) > 0 for at least one s∗. Assume that Gprod, kren, k21 and kint are strictly
positive constants. Then, Q(t) > 0 for all time t > 0.
Proof Assume, for contradiction, that there exists a s∗ such that Q(s∗) = 0. The assumption
on ϕ1 and the continuity of Q allows us to assume that Q(s) > 0 for all s < s∗.
The constraints in (B.2) ensures that β(Q(t− τQ)) > 0.
Then:
d
dt
Q(t) = −(κ(G1(t)) + κδ + β(Q(t)))Q(t) +AQ(t)β(Q(t− τQ))Q(t− τQ)
> −(κ(G1(t)) + κδ + β(Q(t)))Q(t).
Using the result of Lemma 5 and that κ(G1(t)) is a monotonically increasing function for
G1(t) > 0 gives
κ(G1(t)) 6 lim
G1(t)→∞
κ(G1(t)) = 2κ
∗ − κmin = κmax <∞.
Setting ξ = κmax + κδ + fQ gives:
d
dt
Q(t) > −ξQ(t).
An argument similar to that in Lemma 4 ensures that Q(t) > 0 for all t > 0. This contradicts
the existence of s∗ and establishes the positivity of Q(t) for all t > 0. uunionsq
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Lemma 7 Consider the initial value problem P, given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35), with G1,0 +G2,0 > 0, ϕ1(s) > 0 for s ∈ [−τ, 0] with
ϕ1(s∗) > 0 for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and N0 + NR,0 > 0. Assume that
Gprod, kren, k21 and kint are strictly positive constants. Then NR(t)+N(t) > 0 for all t > 0.
Proof A simple calculation gives:
d
dt
(NR(t) +N(t)) = AN (t)κ(G1(t− τN (t)))Q(t− τN (t)) VNM(G1(t))VNM(G1(t−τNM(t)))−γNRNR(t)− γNN(t).
Applying Lemmas 5, 6 and (B.2), the following holds
AN (t)κ(G1(t− τN (t)))Q(t− τN (t))
VNM(G1(t))
VNM(G1(t− τNM(t)))
> 0.
Define α = max[γNR , γN ] and calculate:
d
dt
(NR(t) +N(t)) > −α(NR(t) +N(t)).
An argument similar to that of Lemma 4 gives the positivity of the sum. uunionsq
Lemma 8 Consider the initial value problem P given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35) such that ϕ1(s) > 0 for s ∈ [−τ, 0] with ϕ1(s∗) > 0
for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and
G2,0 6 V [NR,0 +N0]
G1,0 +G2,0 > 0
N0 +NR,0 > 0
Assume that k21 and kint are strictly positive constants. Then, G2(t) 6 V [NR(t) + N(t)]
for all t > 0.
Proof Assume, for contradiction, that there is a time s > 0 with G2(s) > V [NR(t) +N(t)].
Then, there must exist a time T ∗ such that G2(T ∗) = V [NR(T ∗) +N(T ∗)]. At t = T ∗:
d
dt
G2(t)|t=T∗ = −kintG2(T ∗) + k12[(NR(T ∗) +N(T ∗))V −G2(T ∗)](G1(T ∗))sG − k21G2(T ∗)
6 −2max[kint, k21]G2(T ∗)
Lemma 7 ensures that G2(T ∗) = V [NR(T ∗) + N(T ∗)] > 0. Therefore ddtG2(t)|t=T∗ < 0,
which contradicts the MVT and there can be no s. uunionsq
Lemma 9 Consider the initial value problem P given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35) such that ϕ1(s) > 0 for s ∈ [−τ, 0] with ϕ1(s∗) > 0
for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and
G2,0 6 V [NR,0 +N0]
G1,0 +G2,0 > 0
G2,0 > 0
N0 +NR,0 > 0
Assume that Gprod, kren, k21 and kint are strictly positive constants. Then, G2(t) > 0 for
all t > 0.
44 Daniel Caˆmara De Souza, Morgan Craig et al.
Proof Using Lemma 5 and the bound from Lemma 8 gives
k12[(NR(t) +N(t))V −G2(t)](G1(t))sG > 0,
and
d
dt
G2(t) = −kintG2(t) + k12[(NR(t) +N(t))V −G2(t)](G1(t))sG − k21G2(t)
> −2max[kint, k21]G2(t).
An argument similar to Lemma 4 gives the result. uunionsq
Lemma 10 Consider the initial value problem P given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35) such that ϕ1(s) > 0 for s ∈ [−τ, 0] with ϕ1(s∗) > 0
for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and
G2,0 6 V [NR,0 +N0]
G1,0 +G2,0 > 0
G1,0 > 0
G2,0 > 0
N0 +NR,0 > 0
Assume that k21 and kint are positive constants. Then, NR(t) > 0 for all t > 0.
Proof The function AN (t) is positive for all time, the constraints in (B.2), the assumptions
on ϕ1,2 and Lemmas 6 and 5 ensure thatAN (t)κ(G1(t−τN (t)))Q(t−τN (t)) VNM(G1(t))VNM(G1(t−τNM(t))) >
0. Then
d
dt
NR(t) = AN (t)κ(G1(t− τN (t)))Q(t− τN (t)) VNM(G1(t))VNM(G1(t−τNM(t)))
−(γNR + ϕNR (GBF (t)))NR(t),
> −(γNR + ϕNR (GBF (t)))NR(t)
Lemma 8 and the positivity of N(t) + NR(t) and G2(t) bounds GBF ∈ [0, 1]. Therefore,
ϕNR (GBF ) is a continuous function on a compact domain and is therefore bounded below
by 0 and above by ϕmaxNR
. Then
d
dt
NR(t) > −(γNR + ϕmaxNR )NR(t),
and an argument similar to Lemma 4 yields the result. uunionsq
Lemma 11 Consider the initial value problem P given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35) such that ϕ1(s) > 0 for s ∈ [−τ, 0] with ϕ1(s∗) > 0
for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and
G2,0 6 V [NR,0 +N0]
G1,0 +G2,0 > 0
G1,0 > 0
G2,0 > 0
N0 +NR,0 > 0
Assume that k21 and kint are strictly positive constants. Then, N(t) > 0 for all t < 0.
Proof Using (B.2) and the Lemmas 5 and 10 to ensure the positivity of NR(t) and ϕNR
yields:
d
dt
N(t) = ϕNR (GBF (t))NR(t)− γNN(t),
> −γNN(t).
A similar argument to that used in Lemma 4 yields the result. uunionsq
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Together, these results lead to the following theorem.
Theorem 4 Consider the initial value problem P given by equations (2.34a)– (2.34f) and
the ICs and histories given in (2.35) such that ϕ1(s) > 0 for s ∈ [−τ, 0] with ϕ1(s∗) > 0
for at least one s∗, ϕ2 > 0 for s ∈ [−τ, 0] and
G2,0 6 V [NR,0 +N0]
G1,0 +G2,0 > 0
G1,0 > 0
G2,0 > 0
N0 +NR,0 > 0
with IG(t) = 0. Moreover, assume that (C.1) is satisfied along with strictly positive model
parameters. Finally, assume that the history functions ϕ1,2 are positive at least once and
are non-negative in their domain. Then
1. the solutions of P, x(t) = (Q(t), NR(t), N(t), G1(t), G2(t)) remain component wise pos-
itive for all time.
2. the solutions of P, x(t) = (Q(t), NR(t), N(t), G1(t), G2(t)) remain component wise
bounded for all time.
Proof 1. The results of Lemmas 5; 6; 9; 10; and 11 give the result.
2. In [36], the authors prove that solutions of the equation:
d
dt
x(t) = −(δ + β(x(t)))x(t) +AQβ(x(t− τQ))x(t− τQ) (B.4)
are bounded above by a finite x1. Setting δ˜ = κmin + κδ gives:
d
dt
Q(t) = −(κ(G1(t)) + κδ + β(Q(t)))Q(t) +AQ(t)β(Q(t− τQ))Q(t− τQ)
6 (δ˜ + β(Q(t)))Q(t) +AQ(t)β(Q(t− τQ))Q(t− τQ),
which implies that Q(t) is bounded by some Q1.
VNM is an increasing function bounded above by Vmax and bounded below by V (0) > 0.
Finally,
AN (t) = exp
[∫ t−τN
t−τNM
ηNP (G1(s))ds− γNM τNM(t)
]
6 exp[ηmaxNP τNP ].
This gives
d
dt
(NR(t) +N(t)) = AN (t)β(Q(t− τN (t)))Q(t− τN (t)) VNM (G1(t))VNM (G1(t−τN (t))) − γNRNR(t)− γNN(t)
6 exp[ηmaxNP τNP ]f0Q1
Vmax
VNM
(0)
Then, setting K = exp[ηmaxNP
τNP ]f0Q1
Vmax
VNM
(0)
and β = min[γN , γNR ] gives
d
dt
(NR(t) +N(t)) 6 K − β(NR(t) +N(t)). (B.5)
Equation (B.5) is equivalent to
d
dt
(NR(t) +N(t)e
βt) 6 Keβt,
Integrating this inequality gives
NR(t) +N(t) 6
K
β
+ (NR,0 +N0 − K
β
)e−βt 6 K
β
+NR,0 +N0.
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As NR, N are both positive, they are individually bounded by this constant.
Now,
d
dt
(G1(t) +G2(t)) = Gprod − kintG2(t)− krenG1(t)
Setting α = min[kint, kren] gives:
d
dt
(G1(t) +G2(t)) 6 Gprod − α(G1(t) +G2(t))
A similar argument to above gives
G1(t) +G2(t) 6
Gprod
α
+ (G1,0 +G2,0 −
Gprod
α
)e−αt 6 G1,0 +G2,0 +
Gprod
α
. (B.6)
Again, as both G1(t) and G2(t) are positive, they are individually bounded by this constant.
Then, solutions of the mathematical model P with positive initial conditions remain
positive and bounded. uunionsq
C Existence and uniqueness of the Homeostatic Steady State of
the QSP granulopoiesis model
Consider the QSP granulopoiesis model defined by the system of DDEs (2.34), and associated
initial conditions and histories, with strictly positive parameters satisfying the constraints
ϕmaxNR > ϕ
h
NR
, Vmax > 1, bG >
ϕmaxNR
ϕhNR
G∗BF , and bV > G
h
1Vmax. (C.1)
The following results will demonstrate the existence and uniqueness of a homeostasic steady
state of this model.
Proposition 1 Assume that
IG(t) = 0, sG > 0, fQ(AQ − 1) > κh + κδ
and define
G1 =
κintA
h
Nκ
hθQ
γNR + ϕ
h
NR
[
1 +
ϕhNR
γN
](
fQ
AQ − 1
κh + κδ
− 1
) 1
sQ
.
If G1 > Gprod, then the system of DDEs given by (2.35) has a unique positive homeo-
static steady state.
Proof Consider the differential equation given in (2.35). Define
X = (Q,NR, N,G1, G2) and f =
dX
dt
.
The steady states are given implicitly by the solutions of
d
dt
X(t) = 0,
and are denoted by Qh, NhR , N
h, Gh1 , G
h
2 respectively. Moreover, denote the homeostatic
values of each function with the superscript h.
A simple calculation to find the non-zero solution of
d
dt
Q(t) = −(κ(G1(t)) + κδ + β(Q(t)))Q(t) +AQ(t)β(Q(t− τQ))Q(t− τQ) = 0
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gives the expression for the homeostatic steady state of Q(t)
Qh = θQ
[
fQ
AQ − 1
κh + κδ
− 1
]1/sQ
.
The conditions in the statement of Proposition 1 ensure that the steady state is positive.
Using Qh, we calculate the solution NhR of
d
dt
NR(t) = AN (t)κ(G1(t− τN (t)))Q(t− τN (t))
VNM(G1(t))
VNM(G1(t− τNM(t)))−(γNR + ϕNR (GBF (t)))NR(t) = 0.
The homeostatic value is
NhR =
AhNκ
hQh
γNR + ϕ
h
NR
> 0.
The final homeostasis value that can be easily expressed is the solution of
d
dt
N(t) = ϕNR (GBF (t))NR(t)− γNN(t) = 0.
Using the homeostatic value of NhR and solving the steady state equation gives
Nh =
ϕhNR
NhR
γN
.
Now, consider the coupled G-CSF kinetics given by equations (2.34e) and (2.34f) whose
homeostatic sum is expressed as
d
dt
(G1(t) +G2(t)) = Gprod − krenGh1 − kintGh2 = 0. (C.2)
Isolating Gh2 as a function of G
h
1 and substituting into (2.34f)
0 = −kintGh2 + k12[(NhR +Nh)V −Gh2 ](Gh1 )sG − k21Gh2 (C.3)
gives the following exponential polynomial in Gh1 .
F (Gh1 ) = α[G
h
1 ]
sG+1 + β[Gh1 ]
sG + δGh1 − ζ, (C.4)
where
α =
k12kren
kint
, β =
k21
kint
[
V (Nh +NhR)kint −Gprod
]
,
δ = kren
kint + k21
kint
, ζ = Gprod
kint + k21
kint
.
Then, any root of F and the corresponding G2 value from (C.2) will be a solution of
(C.3). The condition
Gprod < V [N
h
R +N
h]kint = G1
guarantees that the coefficients are positive.
A simple calculation shows that
F (0) < 0, F (ζ/δ) > 0.
By the IVT, there must exist a solution Gh1 ∈ (0, ζ/δ) such that
0 = α(Gh1 )
sG+1 + β(Gh1 )
sG + δ(Gh1 )− ζ. (C.5)
Since for all x ∈ R+
F ′(x) = (sG + 1)αxsG + βsGxsG−1 + δ > 0,
thus F is a strictly increasing function and the zero found in (C.5) is unique.
Therefore, the corresponding Gh2 given by (C.2) is unique. The condition 0 < G
h
1 < ζ/δ
together with (C.2) and ζ/δ = Gprod/kren ensures the positivity of G
h
2 . Thus the homeostatic
steady state (Qh, NhR, N
h, Gh1 , G
h
2 ) exists, is positive and unique. uunionsq
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D Stability of the equilibria
D.1 Characteristic equations of the Quartino model
The characteristic equations for the time-rescaled Quartino model (2.30), for the equivalent
distributed delay DDE (2.31), and for the discrete delay DDE model (2.33) have relatively
simple form and are stated explicitly in the main text as equations (3.10) and (3.8). In
contrast the Quartino model (2.2) has a much more complicated form both for general n
and when n = 4 as in Quartino [43], which we derive here.
The Quartino model (2.2) has characteristic equation given by (3.11) where J is the
Jacobian of F in (3.2). Differentiating the terms in (2.2) for general X we obtain the Jacobian
J(X) =

J11 0 0 · · · · · · 0 J1,n+3
J21 −J32 0 · · · · · · 0 J2,n+3
0 J32 −J32 0 · · · 0 J3,n+3
...
. . .
. . .
. . .
. . .
...
...
...
. . . J32 −J32 0 Jn+1,n+3
0 0 · · · 0 J32 −kcirc Jn+2,n+3
0 0 · · · · · · 0 −kANCG Jn+3,n+3

(D.1)
where
J11 = ktr
((
G
G0
)γ
−
(
G
G0
)β)
, J21 = ktr
(
G
G0
)β
, J32 = a
(
G
G0
)β
,
J1,n+3 = −Pktr
G0
(
γ
(
G
G0
)γ−1
− β
(
G
G0
)β−1)
, J2,n+3 =
β
G0
(ktrP − aT1)
(
G
G0
)β−1
,
Jn+2,n+3 =
Tn β a
G0
(
G
G0
)β−1
, Jn+3,n+3 = −ke −NkANC,
Jj,n+3 =
βa
G0
(Tj−2 − Tj−1)
(
G
G0
)β−1
, j = 3, . . . , n+ 1.
Then the characteristic function for the Quartino model (2.2) is the (n+3)-degree polynomial
in λ:
∆(λ) = det(λI− J(X))
= (λ− J11)(λ+ J32)n
(
(λ− kcirc)(λ+ Jn+3,n+3) + kANCGJn+2,n+3
)
− J1,n+3J21(J32)nkANCG (D.2)
+
n+1∑
j=2
(−1)j(λ− J11)(λ+ J32)j−2Jj,n+3(J32)n+2−jkANCG.
This is considerably more complicated than the characteristic function of the time-rescaled
Quartino model which we also stated for general X in equation (3.11). Fortunately (D.2)
does simplify somewhat at the steady states. At both X∗1 and X
∗
2 we have
ktrP = aT1, Tj = Tj−1,
and hence
Tj,n+3 = 0, j = 2, . . . , n+ 1.
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Additionally at X∗2 only, G = G0 implies J11 = 1, while at X
∗
1 only, P = Tn = 0 implies
that T1,n+3 = Tn+2,n+3 = 0. So
J(X∗1) =

J11 0 0 · · · · · · 0 0
J21 −J32 0 · · · · · · 0 0
0 J32 −J32 0 · · · 0 0
...
. . .
. . .
. . .
. . .
...
...
...
. . . J32 −J32 0 0
0 0 · · · 0 J32 −kcirc 0
0 0 · · · · · · 0 − kANCkin
ke
−ke

, (D.3)
with
J11 = ktr
((
kin
G0ke
)γ
−
(
kin
G0ke
)β)
, J21 = ktr
(
kin
G0ke
)β
, J32 = a
(
kin
G0ke
)β
, (D.4)
and
∆1(λ) = det(λI− J(X∗1))
=
(
λ− ktr
((
kin
G0ke
)γ
−
(
kin
G0ke
)β))(
λ+ a
(
kin
G0ke
)β)n
(λ+ kcirc)(λ+ ke) (D.5)
At X∗2 from (D.2) we obtain
∆2(λ) = det(λI− J(X∗2))
= λ(λ+ a)n
(
(λ− kcirc)(λ+ Jn+3,n+3) + kANCGJn+2,n+3
)
− J1,n+3an+1kANCG. (D.6)
Equations (D.5) and (D.6) give the characteristic function as a polynomial of degree n+3 at
the two steady states X∗1 and X
∗
2 of the generalised Quartino model (2.2) for general values
of the parameters, including for the parameters used in Quartino [43] when n = 4 and the
polynomials have degree 7.
D.2 Stability of the equilibria of the Quartino ODE model
The stability of the steady states of the Quartino model (2.2) was already considered in
Theorem 1, which was proved using the alternate time-rescaled forms of the model. Here we
present proofs of stability results directly in the original formulation, mainly to demonstrate
how much more difficult they are.
Proposition 2 The equilibrium point X∗1 of the Quartino model (2.2) is locally asymptot-
ically stable when γ < β and unstable when γ > β.
Proof For the case β > γ, we show asymptotic stability of X∗1 using a Lyapunov function
[39] applied to the first (n+ 2) coordinates of the system.
First consider the dynamics of G(t). Let λ ∈ (0, 1) and suppose N(t) ∈ [0, λN0] for
t ∈ [0, tN], and let
Gratio =
ke + kANCN0
ke + λkANCN0
> 1.
Then from (2.2e) we have d
dt
G > 0 when G/G0 < Gratio, and the positivity of N(t) implies
that d
dt
G 6 0 when G > kin/ke. Hence choosing G(0) ∈ [G0Gratio, (1 + λ)kin/ke], ensures
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that G(t) ∈ [G0Gratio, (1 + λ)kin/ke] for all t ∈ [0, tN], under the assumption that N(t) ∈
[0, λN0] for t ∈ [0, tN]. Now let
V (X(t)) =
1
2
µP (t)2 +
1
2
n∑
j=1
Tj(t)
2 +
1
2
αN(t)2, (D.7)
where the parameters satisfy µ > 0 and α > 0, with values to be specified below. Note that
V (X∗1) = 0, while V (X) > 0 if any of P , Tj , N is non-zero. Then differentiating and using
(2.2) we obtain
d
dt
V (X(t)) = µP (t)
dP
dt
+
n∑
j=1
Tj(t)
dTj
dt
+ αN(t)
dN
dt
= −
(
G(t)
G0
)β (
µ
(
ktr − kP
(
G(t)
G0
)γ−β)
− k
2
tr
2a
)
P (t)2
− a
2
(
G(t)
G0
)β(ktr
a
P (t)− T1(t)
)2
−
n∑
j=2
a
2
(
G(t)
G0
)β
(Tj−1(t)− Tj(t))2
− a
2
(
G(t)
G0
)β
(Tn(t)− αN(t))2 − α
(
kcirc − a
2
(
G(t)
G0
)β
α
)
N(t)2.
Notice that all the terms on the right-hand side are non-positive, except possibly for the
first and last term. But with ktr = kP, β > γ and G(t)/G0 > Gratio > 1 it follows that
ktr − kP
(
G(t)
G0
)γ−β
> 0,
and hence for µ > 0 sufficiently large the coefficient of P (t)2 is strictly negative. Similarly,
since G(t) is bounded above for t ∈ [0, tN] for α > 0 sufficiently small the coefficient of N(t)2
is also strictly negative. It follows that d
dt
V (X(t)) < 0 unless P = Tj = N = 0.
If V (X(t)) <
αλ2N20
2
, then (D.7) implies that N(t) < λN0. Therefore, we choose initial
conditions such that G(0) ∈ [G0Gratio, (1 + λ)kin/ke] and
V (X(0)) <
αλ2N20
2
.
Then since V (X(t)) is nonincreasing, we have N(t) < λN0 for all t > 0, then G(t) ∈
[G0Gratio, (1 + λ)kin/ke] for all t > 0 and V (X(t)) → 0 as t → ∞ which implies that
[P (t), T1(t), . . . , Tn(t), N(t)]→ [0, 0, . . . , 0, 0] as t→∞.
Finally considering (2.2e), we have d
dt
G < 0 if G > kin/ke and
d
dt
G > 0 if G <
kin/(ke + kANCN(t)) with N(t) → 0 as t → ∞, hence G(t) → kin/ke as t → ∞. This
completes the proof of local asymptotic stability of X∗1 when γ < β.
For the case γ > β, we show that X∗1 is unstable, using linearization theory, by showing
there is a real positive characteristic root in this case. The characteristic function evaluated
at X∗1 is given by (D.5) and statisfies ∆1(λ) → +∞ as λ → +∞. Hence, by the IVT, to
show that there exists a positive eigenvalue, λ > 0 such that ∆1(λ) = 0, it is sufficient to
show that ∆1(0) < 0. But from (D.5)
∆1(0) = det(−J(X∗1)) = (−1)n+3 det(J(X∗1)) = (−1)2n+5kcirckeJ11Jn32
= kcirckea
nktr
((
kin
G0ke
)β
−
(
kin
G0ke
)γ)( kin
G0ke
)nβ
.
From the constraint in equation (2.8), we have that kin = G0(ke + kANCN0) > G0ke, then
γ > β and the positivity of all the parameters imply that ∆1(0) < 0 as required. Thus
∆1(X∗1) has a characteristic value λ > 0 and X
∗
1 is unstable. uunionsq
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Proposition 3 The equilibrium point X∗2 of the Quartino model (2.2) is unstable when
γ < β.
Proof Consider the characteristic function ∆2(λ) evaluated at X∗2. From (D.6) we have
∆2(λ)→ +∞ as λ→∞, while recalling that J11 = 0 and using (2.7) and (2.8)
∆2(0) = −J1,n+3ktrankANCG0 = P0k2tr(γ − β)ankANC = anktrkcirc(γ − β)
(
kin
G0
− ke
)
.
From (2.8) we have ke < (ke+kANCN0) = kin/G0, thus ∆2(0) < 0. Thus the IVT guarantees
that (D.6) has at least one real positive root and therefore X∗2 is unstable. uunionsq
D.3 Characteristic Equation of the discrete delay DDE Quartino model
The discrete delay DDE model (2.33), obtained as the n → ∞ limit of the time-rescaled
Quartino model (2.30) has characteristic equation (3.7). The 3× 3 linearisation matrices A
and B from (3.6), are derived by differentiating the terms on the right-hand side of (2.33).
We will denote their entries by Aij and Bij for i, j = {1, 2, 3}. Let us define the ratio between
G-CSF concentrations Gr := G∗/G0 and let Y∗ = (P ∗, N∗, G∗) be a generic steady state
then
A =
A11 0 A130 A22 A23
0 A32 A33
 , B =
 0 0 0ktr 0 0
0 0 0
 , (D.8)
where
A11 = kPG
γ−β
r − ktr, A13 =
P ∗
G∗
(γ − β)kPGγ−βr , A22 = −kcircG−βr ,
A23 =
N∗
G∗
βkcircG
−β
r , A32 = −kANCG∗G−βr , A33 = −(ke + kANCN∗)G−βr .
Using the matrices (D.8) we rearrange the determinant from equation (3.7) and obtain∣∣∣∣∣∣
λ−A11 0 −A13
−ktre−λτ λ−A22 −A23
0 −A32 λ−A33
∣∣∣∣∣∣ = 0,
from where we get the characteristic equation (3.8) with the coefficients a2, a1, a0 and b
given by
a2 = −(A11 +A22 +A33),
a1 = A11(A22 +A33) +A22A33 −A23A32,
a0 = A11(A23A32 −A22A33),
b = A13A32ktr.
(D.9)
Recalling the steady states Y∗1 and Y
∗
2 given, respectively, by (3.16) and (3.17), calculated
with the parameter constraints (2.4) and (2.8), we can evaluate the coefficients in (D.9) at
each steady state. For Y∗1 we have P
∗ = N∗ = 0 which implies that A13 = A23 = 0 and we
have
a2 = kP(1−Gγ−βr ) + (kcirc + ke)G−βr ,
a1 = kP(1−Gγ−βr )(kcirc + ke)G−βr + kcirckeG−βr ,
a0 = kPkcircke(1−Gγ−βr )G−2βr ,
b = 0,
(D.10)
For γ > β we have a0 < 0 in (D.10), since kin > keG0 from the constraint (2.8) and
consequently Gr > 1. Similarly a0 > 0 when γ < β.
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For Y∗2 we have G
∗ = G0, hence Gr = 1 which implies A11 = 0.
a2 = kcirc + ke + kANCN0,
a1 = kcirc(ke + kANCN0(1 + β)),
a0 = 0,
b = (β − γ)kpkcirckANCN0.
(D.11)
D.4 Characteristic Equation of the QSP granulopoiesis model
The QSP granulopoiesis model (2.34) has characteristic equation (3.26). From the DDE of
the QSP granulopoiesis model (2.34) we compute the linearization matrices and indicate
which terms are symmetric and asymmetric. We obtain
A =

A11 A12 0 0 0
0 A22 A23 A24 A25
0 A32 A33 0 A35
0 A42 A43 A44 A45
0 A52 A53 A54 A55
 , B =

B11 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
 , (D.12)
C =

0 0 0 0 0
C21 0 0 C24 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
 , D =

0 0 0 0 0
0 0 0 D24 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
 , E =

0 0 0 0 0
0 0 0 E24 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
 , (D.13)
with
A11 = −κ∗ − κδ − β(Q∗)−Q∗
dβ
dQ
(Q∗), A12 = −Q∗ dκ
dG1
(G∗1),
A22 = −γNR − ϕ∗NR −N∗R
dϕNR
dGBF
(G∗BF )
∂GBF
∂NR
(N∗R , N
∗, G∗2),
A23 = −N∗R
dϕNR
dGBF
(G∗BF )
∂GBF
∂N
(N∗R , N
∗, G∗2), A24 =
A∗Nκ
∗Q∗
VNM(G
∗
1)
dVNM
dG1
(G∗1),
A25 = −A35 = −N∗R
dϕNR
dGBF
(G∗BF )
∂GBF
∂G2
(N∗R , N
∗, G∗2),
A32 = N
∗
R
dϕNR
dGBF
(G∗BF )
∂GBF
∂NR
(N∗R , N
∗, G∗2) + ϕ
∗
NR
,
A33 = N
∗
R
dϕNR
dGBF
(G∗BF )
∂GBF
∂N
(N∗R , N
∗, G∗2)− γNR ,
A42 = A43 = −A52 = −A53 = −k12V (G∗1)sG ,
A44 = −kren − k12[(N∗R +N∗)V −G∗2]sG(G∗1)sG−1, A45 = k12(G∗1)sG + k21,
A54 = k12[(N
∗
R +N
∗)V −G∗2]sG(G∗1)sG−1, A55 = −kint − k12(G∗1)sG − k21,
B11 = AQ
(
β(Q∗) +Q∗
dβ
dQ
(Q∗)
)
, C21 = κ
∗A∗N , C24 = A
∗
NQ
∗ dκ
dG1
(G∗1),
D24 = −
A∗Nκ
∗Q∗
VNM(G
∗
1)
dVNM
dG1
(G∗1) = −A24, E24 = κ∗Q∗
dA˜N
dG˜1
(G∗1) = κ
∗Q∗τNPA
∗
N
dηNP
dG1
(G∗1).
